Gastric retention drug dosage forms and their preparation methods
Patent Information
- Application Number
- TW110140451
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-10-27
- Filing Date
- 2021-10-29
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2041-10-28
Smart Images

Figure TWG2TB001919895_001 
Figure TWG2TB001919895_002 
Figure TWG2TB001919895_003
Abstract
Description
[Technical Field]
[0001] This invention relates to pharmaceutical dosage forms, and more specifically, to a pharmaceutical dosage form that can be retained in the stomach or other parts of the digestive tract. [Previous Technology]
[0002] The retention time of a drug at the site of action is a crucial factor affecting its final therapeutic outcome. Rapid gastric emptying and short gastrointestinal transit times often prevent traditional oral drug delivery systems from achieving effective retention at the site of action, thus impacting the drug's final bioavailability. In some cases, the drug is even expelled from the stomach or upper digestive tract before being fully released, severely affecting therapeutic efficacy. To address these issues, drug delivery systems capable of retention in the stomach and other sites have been developed. These systems primarily rely on increasing structural size, improving surface adhesion, or altering overall density to achieve drug retention in the gastrointestinal tract, thereby reducing the frequency of administration, improving drug efficacy, and further increasing patient compliance.
[0003] However, existing drug delivery systems that can remain in the gastrointestinal tract usually have complex dosage forms and high manufacturing costs. At the same time, the specific administration process of some existing drug delivery systems still relies on the assistance of structures such as gastroesophageal tubes, gastric tubes, or capsules, which requires professional drug administration skills or drug filling procedures, affecting the convenience of use and production efficiency. [Summary of the Invention]
[0004] The present invention provides a drug dosage form that can be used to achieve retention in the stomach or other parts of the digestive tract, thereby prolonging the retention time of the drug at the site of action, reducing the frequency of administration, increasing patient tolerance, and improving clinical efficacy.
[0005] In one aspect of the invention, a pharmaceutical dosage form is provided, comprising: a pharmaceutical unit containing a drug; at least one unfolding member connected to the pharmaceutical unit and configured to have a contracted shape adjacent to the pharmaceutical unit and an unfolded shape distant from the pharmaceutical unit; and a retaining member connected to the at least one unfolding member and applying the restraining force to the at least one unfolding member such that the unfolding member is in the contracted shape; wherein the retaining member comprises a water-soluble material and the retaining member is configured to remove the restraining force on the unfolding member when the water-soluble material dissolves, thereby allowing the at least one unfolding member to change from the contracted shape to the unfolded shape.
[0006] In some embodiments, the unfolding member includes at least one elastic portion configured to allow the unfolding member to contract into a shape close to the drug unit under the action of a constraint force, and to return to an unfolded shape away from the drug unit when the constraint force is removed.
[0007] In some embodiments, the retaining member at least partially covers the drug unit and at least one unfolding member so that the at least one unfolding member is in a contracted shape.
[0008] In some embodiments, the retaining member is disposed between and connected to the drug unit and the deploying member, such that the deploying member is in a contracted shape.
[0009] In some embodiments, the drug dosage form includes a plurality of unfolding members, and the retaining member connects at least two unfolding members so that the at least two unfolding members are in a contracted shape.
[0010] In some embodiments, the elastic portion is located at one end of the deploying member adjacent to the drug unit.
[0011] In some embodiments, the unfolding member has a reduced thickness portion at one end adjacent to the drug unit.
[0012] In some embodiments, the unfolding member has a strip-shaped, sheet-shaped, curved, petal-shaped, or rod-shaped shape.
[0013] In some embodiments, the drug dosage form includes a plurality of unfolding members that are generally uniformly distributed along the periphery of the drug unit.
[0014] In some embodiments, the drug unit includes a hollow chamber connected to the drug unit. In some embodiments, the hollow chamber is connected to an unfolded construct. In some embodiments, the hollow chamber is contained within the drug unit.
[0015] In some embodiments, the drug unit includes a shell and a drug-containing core.
[0016] In some embodiments, the drug unit housing and the deployment member contain the same body material.
[0017] In another aspect of the present invention, a method for preparing a pharmaceutical dosage form using three-dimensional printing technology is provided, characterized in that the method includes: printing a pharmaceutical unit containing a drug and at least one unfolding member to connect the unfolding member to the pharmaceutical unit, configuring the unfolding member from an unfolded shape to a contracted shape close to the pharmaceutical unit; directly printing a holding member to connect the holding member to the at least one unfolding member, and applying the constraint force to the at least one unfolding member to place the unfolding member in the contracted shape; wherein the holding member comprises a water-soluble material, and the holding member is configured to remove the constraint force on the unfolding member when the water-soluble material dissolves, thereby allowing the at least one unfolding member to change from the contracted shape to the unfolded shape.
[0018] In some embodiments, the at least one unfolding member is printed to include at least one elastic portion, the elastic portion being configured to cause the unfolding member to take on a contracted shape close to the drug unit under the action of a constraint force, and to return to an unfolded shape away from the drug unit when the constraint force is removed.
[0019] In some embodiments, the print holding member includes: printing the holding member such that the holding member at least partially covers or adheres the drug unit and at least one unfolding member, thereby placing the at least one unfolding member in a contracted shape.
[0020] In some embodiments, the print holding member includes: printing the holding member such that the holding member is positioned between and connected to the drug unit and the unfolding member, thereby placing the unfolding member in a contracted shape.
[0021] In some embodiments, the steps of printing at least one unfolding member and printing a holding member are performed simultaneously or alternately by different print heads.
[0022] In some embodiments, the unfolding member is printed as having a reduced thickness portion at one end adjacent to the drug unit.
[0023] In some embodiments, printing at least one unfolding member includes: printing at least one unfolding member in an unfolded shape; moving the at least one unfolding member such that the unfolding member is in a contracted shape.
[0024] In some embodiments, the drug unit includes a first portion containing a drug and a second portion not containing a drug, and the first portion containing the drug is printed after the step of printing and holding the member is completed.
[0025] In another aspect of the invention, a pharmaceutical dosage form is provided, characterized in that the pharmaceutical dosage form comprises: a pharmaceutical unit containing a drug, at least a portion of the pharmaceutical unit being curved or folded; a retaining member connected to the pharmaceutical unit and applying a restraining force to the pharmaceutical unit such that at least a portion of the pharmaceutical unit retains the curved or folded shape; wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the restraining force on the pharmaceutical unit when the water-soluble material dissolves, thereby allowing at least a portion of the pharmaceutical unit to unfold from the curved or folded shape.
[0026] In some embodiments, the drug unit is configured as a spiral shape having a radius of curvature that gradually increases from the inside to the outside, and the retaining member at least partially fills the gaps in the spiral shape of the drug unit.
[0027] In some embodiments, the drug unit includes a shell layer and a drug layer, and the shell layer is made of a hydrophobic material.
[0028] In some embodiments, the drug layer comprises a hydrophilic material.
[0029] In some embodiments, the drug layer includes a first portion and a second portion, wherein the drugs contained in the first portion and the second portion are different.
[0030] In some embodiments, the drug unit is generally elongated when unfolded.
[0031] In another aspect of the present invention, a method for preparing a pharmaceutical dosage form using three-dimensional printing technology is provided, characterized in that the method includes: printing a pharmaceutical unit containing a drug such that at least a portion of the pharmaceutical unit is curved or folded; printing a retaining member such that the retaining member is connected to the pharmaceutical unit and a restraining force is applied to the pharmaceutical unit so that at least a portion of the pharmaceutical unit retains the curved or folded shape; wherein the retaining member comprises a water-soluble material and the retaining member is configured to remove the restraining force on the pharmaceutical unit when the water-soluble material dissolves, thereby allowing at least a portion of the pharmaceutical unit to unfold from the curved or folded shape.
[0032] In some embodiments, the drug unit is configured as a spiral shape having a radius of curvature that gradually increases from the inside to the outside, and the retaining member at least partially fills the gaps in the spiral shape of the drug unit.
[0033] In some embodiments, the drug unit includes a shell layer and a drug layer, and the shell layer is made of a hydrophobic material.
[0034] In one aspect of the invention, a pharmaceutical dosage form is provided, comprising: an unfolding member including at least one elastic portion configured to allow the unfolding member to contract under a restraining force and to return to an unfolded shape when the restraining force is removed; and a retaining member disposed around the unfolding member and applying a restraining force to the unfolding member to maintain the unfolding member in a contracted shape; wherein the retaining member comprises a water-soluble material and is configured to remove the restraining force on the unfolding member when the water-soluble material dissolves, thereby allowing the unfolding member to at least partially unfold.
[0035] In some embodiments, the retaining member includes a first portion and a second portion, the unfolding member is connected to the first portion, and the second portion contains a water-soluble material, and when the water-soluble material in the second portion dissolves, the retaining member removes the restraining force on the unfolding member, thereby allowing the unfolding member to unfold at least partially.
[0036] In some embodiments, the first portion includes a first drug and the second portion includes a second drug.
[0037] In some embodiments, the first portion includes at least one compartment in which the first drug is disposed.
[0038] In some embodiments, the unfolding member includes a first part and a second part, and the first part of the unfolding member dissolves in gastric juice at a rate less than the second part of the retaining member dissolves in gastric juice.
[0039] In some embodiments, the first portion of the unfolding member includes a drug.
[0040] In some embodiments, the unfolding member further includes a third part, the first part of the unfolding member is connected to the second part of the unfolding member by the third part of the unfolding member, and when the third part dissolves, the connection between the first part and the second part of the unfolding member is broken.
[0041] In some embodiments, the second and third portions of the unfolding member comprise hydrophobic and enteric materials.
[0042] In some embodiments, the first portion of the unfolding member extends generally along a first direction, while the second portion of the unfolding member extends generally along a second direction, and the first and second portions of the unfolding member are intersected and connected to each other.
[0043] In some embodiments, the first portion of the deployable member includes at least one internal compartment, and the internal compartment is provided with a drug.
[0044] In some embodiments, when in the contracted configuration, the elastic portion of the unfolding member is configured to extend substantially along a plane.
[0045] In some embodiments, when the water-soluble material of the retaining member is at least partially dissolved, the length of the drug dosage form in at least one direction is greater than or equal to 16 mm.
[0046] In some embodiments, the unfolding member is configured to fully unfold within at least 10 minutes after entering the gastric fluid.
[0047] In one aspect of the present invention, a method for preparing a pharmaceutical dosage form using three-dimensional printing technology is provided, characterized in that the method comprises: printing an unfolding member, the unfolding member including at least one elastic portion, the elastic portion being configured to allow the unfolding member to contract under a constraint force and to return to an unfolded shape when the constraint force is removed; applying a constraint force to the unfolding member to maintain the unfolding member in a contracted shape; printing a retaining member to retain the constraint force on the unfolding member, thereby maintaining the unfolding member in the contracted shape; wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the constraint force on the unfolding member when the water-soluble material dissolves, thereby allowing the unfolding member to at least partially unfold.
[0048] In some embodiments, the retaining member includes a first portion and a second portion, and the method further includes: after printing the unfolding member, printing the first portion of the retaining member such that the unfolding member is connected to the first portion of the retaining member; applying a constraint force to the unfolding member by means of the first portion of the retaining member, thereby keeping the unfolding member in the contracted shape.
[0049] In some embodiments, the method further includes: printing a second portion of the retaining member, wherein the second portion comprises a water-soluble material, and when the water-soluble material of the second portion dissolves, the retaining member removes the constraint force on the unfolding member, thereby allowing the unfolding member to unfold at least partially.
[0050] In one aspect of the present invention, a method for preparing a pharmaceutical dosage form using three-dimensional printing technology is provided, characterized in that the method includes: printing a retaining member; printing an unfolding member under the constraint of the retaining member within a region surrounded by the retaining member, such that the unfolding member is connected to the retaining member, the unfolding member including at least one elastic portion configured to at least partially unfold the unfolding member when the constraint applied by the retaining member is removed; wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the constraint on the unfolding member when the water-soluble material dissolves, thereby allowing the unfolding member to at least partially unfold.
[0051] In some embodiments, the unfolded component after printing is heat-treated to increase the elasticity of the elastic portion.
[0052] The above is an overview of the present invention. There may be simplifications, generalizations, and omissions of details. Therefore, those skilled in the art should recognize that this part is merely illustrative and not intended to limit the scope of the invention in any way. This overview is neither intended to identify the key or essential features of the claimed name nor to serve as an aid in determining the scope of the claimed name.
Implementation Method
[0099] In the following detailed description, reference is made to the drawings that form a part thereof. The illustrative embodiments described in the detailed description, drawings, and claims are not intended to be limiting. Other embodiments may be adopted, and other changes may be made, without departing from the spirit or scope of the subject matter of the invention. Before a more detailed description of the invention, it should be understood that the invention is not limited to the specific embodiments described, and that it is of course subject to change. It should also be understood that the terminology used in the invention is for the purpose of describing specific embodiments only and is not intended to be limiting, as the scope of the invention is defined only by the appended claims.
[0100] When providing numerical ranges, it should be understood that every midpoint between the upper and lower limits of the range, and any other midpoint within the range of such expressions, up to one-tenth of the unit of the lower limit, is included within the scope of this invention, unless the context otherwise expresses. The upper and lower limits of these smaller ranges may be independently included in smaller ranges and are also included within the scope of this invention, subject to any specific excluded limit values within said range. When said range includes one or two limit values, the range excluding one or both limit values is also included within the scope of this invention. References to “about” values or parameters herein include (and describe) variations of that value or parameter itself. For example, a description of “about X” includes a description of “X”.
[0101] All publications and patents referenced in this specification are incorporated herein by reference, which means that each publication or patent is specifically and individually indicated to be incorporated by reference, and is incorporated herein by reference to disclose and describe methods and / or materials relating to the referenced publication. Any publications referenced were published prior to the filing date of this invention, and the provided publication date may differ from the actual publication date, which may require separate confirmation.
[0102] Those skilled in the art will understand upon reading this invention that the various embodiments described and explained herein have discrete components and characteristics, and can be easily separated or combined with the characteristics of any other embodiments without departing from the scope or spirit of this invention. Any method described may be performed in the order of the events described or in any other logically possible order.
[0103] Before describing the embodiments of the present invention in detail, unless otherwise expressly stated, it should be understood that the present invention is not limited to specific materials, reagents, reaction raw materials, production techniques, etc., and these can be changed. It should also be understood that the terminology used in the present invention is for the purpose of describing specific embodiments only and is not intended to be limiting. The steps may also be performed in logically possible different orders in the present invention.
[0104] The terms “comprising,” “including,” “containing,” “having,” and other similar expressions used herein shall be equivalent in meaning, and the one or more elements listed after these words do not constitute an exhaustive list, nor do they indicate limitation to only one or more of the listed elements. For example, an article that “comprising” components A, B, and C may consist of components A, B, and C (i.e., contain only), or may contain not only components A, B, and C, but also one or more other components.
[0105] It should be noted that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural objects unless the context clearly indicates otherwise. Thus, for example, “compound” includes multiple compounds. Several terms will be given for reference in this specification and the claims below, and will be defined to have the following meanings unless clearly intended to the contrary.
[0106] Drug Dosage Form I
[0107] This invention provides a pharmaceutical dosage form that can achieve retention in the stomach or other parts of the digestive tract, thereby prolonging the retention time of the drug at the site of action, reducing the frequency of administration, increasing patient tolerance, and improving clinical efficacy. In some embodiments, the pharmaceutical dosage form may be formed by 3D printing.
[0108] FIG1 shows a perspective view of a drug dosage form 100 according to an embodiment of the present invention when its unfolding member 101 is in an unfolded shape. FIG2 shows a perspective view of the drug dosage form 100 shown in FIG1 when its unfolding member 101 is in a contracted shape.
[0109] As shown in Figures 1 and 2, the drug dosage form 100 includes a drug unit 102 and two deployment members 101 connected thereto. The deployment members 101 have an elastic portion 111 and an inelastic portion 112. The elastic portion 111 is configured such that the deployment member 101, under the action of a constraint force, presents a contracted shape close to the drug unit 102 as shown in Figure 2, and when the constraint force is removed, it returns to the unfolded shape away from the drug unit 102 as shown in Figure 1.
[0110] Although not shown in Figure 2, in some embodiments, the pharmaceutical dosage form 100 further includes a retaining member connected to the unfolding member 101. The retaining member exerts a restraining force on the unfolding member 101 to bring it into a contracted shape as shown in Figure 2. The retaining member comprises a water-soluble material and is configured such that when the water-soluble material dissolves in an aqueous solution or body fluid, the retaining member can be at least partially detached or collapsed, thereby removing the restraining force on the unfolding member 101. This allows the unfolding member 101 to move into the unfolded shape shown in Figure 1.
[0111] During use, the drug dosage form 100, constrained by the retaining member into a contracted shape as shown in FIG2, is delivered orally or by other means of administration to the site of administration (e.g., the stomach or other parts of the upper digestive tract). Subsequently, due to the rapid dissolution of the water-soluble material in the retaining member, the unfolding member 101 moves to the unfolded shape as shown in FIG1, resulting in an increase in its overall structural size. Since the structural size of the unfolded shape is generally difficult to pass through the relatively narrow section of the site of administration (e.g., the pylorus of the stomach), the drug dosage form 100 is retained at the site of administration, prolonging its retention time and improving bioavailability.
[0112] The unfolded size of the drug dosage form 100 is configured to provide the aforementioned retention effect. Specifically, when used to provide the retention effect, the unfolded size of the drug dosage form is greater than or equal to 12 mm, preferably greater than or equal to 18 mm. As used herein, "unfolded size" refers to the maximum straight-line distance between any two points on the unfolded drug dosage form 100.
[0113] It should be noted that although the drug dosage form 100 shown in Figures 1 and 2 includes an elastic portion 111 to enable the unfolding member 101 to automatically recover from the contracted shape shown in Figure 2 to the unfolded shape shown in Figure 1 when the constraint force is removed, in some embodiments, the drug dosage form 100 may not include the elastic portion 111, which is configured to move from the contracted shape to the unfolded shape under the action of an external force. Specifically, in some embodiments, the elastic portion 111 of the drug dosage form 100 is not made of an elastic material as shown in Figures 1 and 2, but its thickness is set to be less than that of its adjacent portions. Since the portion with reduced thickness is relatively more flexible, the unfolding member 101 can still easily unfold from the contracted shape shown in Figure 2 to the unfolded shape shown in Figure 1 under the action of gastric juice or other substances. The drug dosage form 100 constructed with this reduced thickness portion can achieve a similar unfolding effect without the need for special use of an elastic material, thereby effectively reducing costs. Furthermore, since no elastic material is required, when printing this drug dosage form using 3D printing technology, its unfolding components can be printed entirely using the same material, avoiding multiple switching of the print head. At the same time, the drug dosage form can also be printed directly in a shrunken shape, thereby effectively improving the production efficiency of the final product.
[0114] Expanding components
[0115] As shown in Figures 1 and 2, the unfolding member 101 is strip-shaped and moves from an unfolded shape to a contracted shape by winding around the cylindrical outer peripheral wall of the drug unit 102. In some embodiments, the unfolding member 101 may also have a petal-shaped, rod-shaped, plate-shaped, spiral-shaped, or any other shape suitable for bending or folding. In some embodiments, the unfolding member 101 can be moved from an unfolded shape to a contracted shape by bending or folding up and down, zigzag folding, or winding in any direction.
[0116] Although the drug dosage form 100 shown in the figure includes two unfolding members 101, in some embodiments, the drug dosage form may include any other number of unfolding members 101, such as 1, 2, 3, 4, 6, 7, 8, 9, etc. The two unfolding members 101 shown in Figure 1 are generally evenly distributed around the outer peripheral wall of the drug unit 102. In some embodiments, the drug dosage form 101 may include four strip-shaped unfolding members that are generally evenly distributed along the outer periphery of the drug unit, which move from an unfolded shape to a contracted shape by winding around the cylindrical outer periphery of the drug unit 102.
[0117] Figure 3 shows a perspective view of a drug dosage form 200 according to an embodiment of the present invention when its unfolding member 201 is not fully in a contracted shape. Figure 4 shows a perspective view of the drug dosage form 200 shown in Figure 3 when its unfolding member 201 is in a contracted shape.
[0118] Specifically, in the embodiments shown in Figures 3 and 4, the drug dosage form 200 has a relatively long strip-shaped unfolding member 201 that is wound around the outer periphery of the drug unit 202 in one direction to move from an unfolded shape to a contracted shape as shown in Figure 4.
[0119] FIG5 shows a perspective view of a drug dosage form 300 according to an embodiment of the present invention when its unfolding member 301 is in an unfolded shape. FIG6 shows a perspective view of the drug dosage form 300 shown in FIG5 when its unfolding member 301 is in a contracted shape.
[0120] Specifically, in the embodiments shown in Figures 5 and 6, the drug dosage form 300 has five petal-shaped unfolding members 301. One end of each petal-shaped unfolding member 301 is attached to the lower surface of the drug unit 302 (or to the lower half of the outer peripheral wall of the drug unit 302), and its other end can be folded towards the drug unit 302. The upper ends of the plurality of petal-shaped unfolding members 301 converge with each other to move from the unfolded shape shown in Figure 5 to the contracted shape shown in Figure 6.
[0121] FIG7 shows a perspective view of a drug dosage form 400 according to an embodiment of the present invention when its unfolding member 401 is in an unfolded shape. FIG8 shows a perspective view of the drug dosage form 400 shown in FIG7 when its unfolding member 401 is in a contracted shape.
[0122] Specifically, in the embodiments shown in Figures 7 and 8, the drug dosage form 400 has four strip-shaped unfolding members 401. One end of each unfolding member 401 is attached to one side of the bottom of the cube or cuboid-shaped drug unit 402. The other end of the strip-shaped unfolding member 401 can be folded toward the drug unit 402 to move from the unfolded shape shown in Figure 7 to the contracted shape shown in Figure 8.
[0123] Although not shown in the figures, in some embodiments, the drug dosage form may also include a floating component with one or more cavities. In other embodiments, the floating component may be constructed as a honeycomb or mesh structure with a fill rate of less than 100%, and the fill rate may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, etc., to provide buoyancy for the drug dosage form in gastric juice, thereby further improving the retention effect of the drug dosage form. In some embodiments, the floating component is connected to the drug unit. In some embodiments, the floating component is connected to the deployment mechanism. In some embodiments, the floating component is located inside the drug unit. In some embodiments, the surface of the deployment mechanism is made of a hydrophobic material. In some embodiments, the deployment component may also contain the drug. In some embodiments, the deployment component is obtained by 3D printing technology.
[0124] Referring again to Figures 1 and 2, the elastic portion 111 of the unfolding member 101 is located at one end of the unfolding member 101 adjacent to the drug unit 102, thereby facilitating the pivoting of the unfolding member 101 about the elastic portion 111 between an unfolded shape and a contracted shape, and allowing the unfolding member 101 as a whole to have a large pivoting angle, for example, 60 degrees to 180 degrees, or preferably, 90 degrees to 120 degrees. In other embodiments, the elastic portion may also be located at other locations on the unfolding member 101, such as in the middle of the unfolding member 101 or at the other end away from the drug unit 102. Furthermore, in some embodiments, each unfolding member 101 may include multiple elastic portions spaced apart from each other, and each elastic portion allows the non-elastic portion of the unfolding member 101 to which it is connected to to deflect in the same or different directions. In other embodiments, the unfolding member 101 may be entirely constructed of an elastomeric material, so that the unfolding member can contract to any desired contracted shape and more easily and automatically return to the unfolded shape after the water-soluble material of the member has dissolved. It is understandable that the unfolded shape can be achieved by adjusting the stress distribution and density of the elastic material.
[0125] Although the thickness of the elastic portion 111 of the display member 101 shown in Figures 1 and 2 is thinner than the thickness of the non-elastic portion 112, in some embodiments, the elastic portion 111 may also have the same thickness as the non-elastic portion 112. It should be noted that in some embodiments, the elastic portion 111 of the unfolding member 101 may be made of a different material than the non-elastic portion 112, and the elastic portion 111 may include an elastic material with a high elastic modulus; however, in other embodiments, the elastic portion 111 may also be made of the same material as the non-elastic portion 112, and in the elastic portion, the unfolding member 101 may have a reduced thickness portion, which can provide the elastic deformation required to constrain the unfolding member 101, and the support force required to move the unfolding member 101 when it is released. In other words, because the reduced thickness portion is relatively more flexible, the unfolding member 101 can still easily unfold from the contracted shape shown in Figure 2 to the unfolded shape shown in Figure 1 under the action of gastric juice or other substances.
[0126] In some embodiments, the elastic portion 111 of the unfolding member 101 may be made of any elastic material suitable for 3D printing. Specifically, the elastic material may have a low glass transition temperature (Tg), and typically exhibits good elasticity, a low elastic modulus, a large maximum elongation, high toughness, or low rigidity at room temperature, thus combining the properties of both plastics and rubber. The elastic portion 111, including this elastic material, can be transformed into any other shape under external force, and when the external force is removed, it can return to its initial shape to the greatest extent possible. Furthermore, the elastic material can be processed into a melt at high temperatures and has relatively insignificant creep properties, thus being suitable for printing the elastic portion of an unfolding member of any desired shape or structure using 3D printing methods.
[0127] Specifically, the material used in the elastic part 111 includes a polymeric elastic material, which can be any one or a combination of the following materials: shape memory polymer (SMP), liquid crystal elastomer (LCE), hydrogel (e.g., Tecophilic™ produced by Lubrizol), thermoplastic elastomer (TPE) (e.g., styrenic block copolymers (TPS (TPE-s)), thermoplastic polyolefin elastomers (TPO (TPE-o)), thermoplastic vulcanizates (TPV (TPE-v or TPV)), thermoplastic polyurethanes (TPU), thermoplastic copolyesters (TPC (TPE-E)), and thermoplastic polyamides (TPA). (TPE-A)), polylactic acid (PLA), acrylonitrile-butadiene-styrene terpolymer (ABS), polyethylene (PE), polypropylene (PP), high-impact polystyrene (HIPS), polybutylene adipate / terephthalate (PBAT), acrylonitrile-butadiene-acrylate (ASA), polyamide (PA), polybutene (PB), polyethylene terephthalate (PET), polyvinylidene fluoride (PVDF).
[0128] Among them, TPE polymers mainly include CAWITON, THERMOLAST K, THERMOLAST M, Arnitel, Hytrel, Dryflex, Mediprene, Kraton, Pibiflex, Sofprene, and Laprene. Meanwhile, styrene block copolymers include CAWITON, THERMOLAST K, THERMOLAST M, Sofprene, Dryflex, and aprene. Thermoplastic polyurethanes include Laripur, Desmopan, and Elastollan. Thermoplastic vulcanized rubbers include Sarlink, Santoprene, Termoton, Solprene, THERMOLAST V, Vegaprene, and Forprene. Thermoplastic olefin elastomers include For-Tec E, Engage, and Ninjaflex.
[0129] In addition to the above-mentioned elastic material, in some embodiments, the material used for the elastic part 111 also includes a plasticizer. The plasticizer may be any one or a combination of the following materials: triethyl citrate (TEC), vitamin E polyethylene glycol succinate (TPGS), acetic acid, acetylated triethyl citrate, tributyl citrate, o-acetylated tributyl citrate, polyhydroxy 15-hydroxystearate, polyoxyethylene-40 hydrogenated castor oil, polyoxyethylene ether (35) castor oil, dibutyl sebacate, diethyl phthalate, glycerin, methyl 4-hydroxybenzoate, castor oil, oleic acid, triacetic acid, and polyalkylene glycol.
[0130] Furthermore, the material used in the elastic part 111 may further contain other additives, which may be any one or a combination of the following materials: acacia, alginate, alginic acid, aluminum acetate, butylparaben, butylated hydroxytoluene, citric acid, calcium carbonate, candelilla wax, croscarmellose sodium carboxymethyl cellulose, confectionery sugar, colloidal silicon dioxide, cellulose, ordinary or anhydrous calcium phosphate, carnauba wax, corn starch, calcium carboxymethyl cellulose, calcium disodium EDTA, dicalcium hydrogen phosphate dehydrate, cetylpyridine, dicalcium hydrogen phosphate, tricalcium phosphate, dicalcium hydrogen phosphate, disodium hydrogen phosphate, dimethyl silicate oil, sodium erythritol, EDTA, gelatin Glyceryl monooleate, iron oxide, iron oxide, iron oxide yellow, iron oxide red, lactose (hydrated, anhydrous, monohydrate or spray-dried), microcrystalline cellulose, magnesium carbonate, magnesium oxide, methylparaben, polysorbate 80, propylparaben, potassium bicarbonate, potassium sorbate, potato starch, phosphoric acid, polyoxyethylene (40) stearate, sodium glycolate ferulic acid ester, starch pregelatinization, sodium croscarmellose, sodium dodecyl sulfate, starch, silicon dioxide, sodium benzoate, sucrose, sorbic acid, sodium carbonate, sodium saccharin, sodium alginate, silicone, dehydrated sorbitan monooleate, sodium chloride, sodium metabisulfite, dehydrated sodium citrate, sodium starch, sodium carboxymethyl cellulose, succinic acid, sodium propionate, titanium dioxide, talc.
[0131] In some embodiments, the elastic portion 111 may be eroded so that the drug formulation can be expelled from the stomach. In some embodiments, the elastic portion is completely eroded in the stomach for 8 to 72 hours. In some embodiments, the elastic portion is completely eroded in the stomach for at least 8, 10, 12, 14, 16, 18, 20, 22, 24, 36, 48, or 72 hours.
[0132] Drug Unit
[0133] As shown in Figures 1 and 2, the drug unit 102 is constructed as a cylinder; however, in some embodiments, the drug unit 102 may also be any other shape, including but not limited to a capsule, cylinder, sphere, ellipsoid, triangular prism, pentagonal prism, bullet-shaped, arrowhead-shaped, tetrahedral, cone, frustum, amygdala, cuboid, cube, or a combination thereof. In some embodiments, the size and shape of the drug unit are configured to be suitable for individual oral administration.
[0134] In some embodiments, the drug unit includes a shell, a drug-containing core, and further includes a drug-free plug or intermediate layer; the drug unit is made of a thermoplastic material, including hydrophilic polymers, hydrophobic polymers, expandable polymers, non-swellable polymers, porous polymers, non-porous polymers, soluble polymers, or non-soluble polymers.
[0135] In some embodiments, the pharmaceutical dosage form disclosed herein includes at least one compartment within the pharmaceutical unit. As used herein, "compartment" refers to a space, portion, or chamber defined or separated by the pharmaceutical unit. A compartment can be either closed or open (i.e., with openings). A compartment can be any geometry that facilitates the loading of a drug. In some embodiments, the compartment shape can be disc-shaped, pyramid-shaped, columnar, or conical. In some embodiments, the compartment shape is specially designed to release the drug at a specific rate. In some embodiments, the compartment shape can be capsule-shaped, wedge-shaped, triangular-ridged, disc-shaped, pyramid-shaped, columnar, cubic, elliptical, or conical.
[0136] In some embodiments, the pharmaceutical unit described herein includes an open compartment formed by an outer shell, the interior of which is a drug-containing core comprising a drug and a sustained-release material; when administered to the human body, the drug is released slowly. In some embodiments, the drug is fully released at least 8h, 10h, 12h, 14h, 16h, 18h, 20h, 22h, 24h, 36h, 48h, or 72h.
[0137] In some embodiments, the drug unit described herein includes an unsealed compartment formed of a shell material, the interior of which is a drug-containing core, and the compartment is sealed by a drug-free stopper; when the drug is administered to the human body, the stopper first comes into contact with and dissolves in the gastric juice, and after the stopper has completely dissolved, the drug-containing core is exposed, thereby achieving delayed drug release. In some embodiments, the drug-containing core has a multi-layered structure, the multi-layered structure including multiple drug-containing layers and intermediate layers stacked together, to achieve pulsed drug release.
[0138] In some embodiments, the pharmaceutical unit described herein includes a plurality of open compartments formed of a shell material, these compartments being arranged side-by-side or in back-to-back contact. In some embodiments, the drug-containing core is partially surrounded by the shell. In some embodiments, the drug-containing core is separated by a partial shell or intermediate layer. In some embodiments, the different compartments are sealed by drug-free stoppers; in some embodiments, the stoppers are of the same length; in some embodiments, the stoppers are of different lengths; in some embodiments, the stoppers are of the same material; in some embodiments, the stoppers are of different materials. In some embodiments, the compartments do not contain stoppers.
[0139] Medicated kernel
[0140] In some embodiments, the drug-containing core includes a drug and a sustained-release material. In some embodiments, the drug-containing core is formed by mixing the drug and the sustained-release material, hot-melt extrusion, and printing.
[0141] In some embodiments, the drug-containing core has a multi-layer structure, the multi-layer structure including a drug-containing layer and an intermediate layer, the drug-containing layer and the intermediate layer being stacked alternately. In some embodiments, the drug-containing layer is an immediate-release (IR) layer, the IR layer including the drug and having an immediate-release curve; in some embodiments, the drug-containing layer is an extended-release (ER) layer, the ER layer including the drug and having an extended-release curve. In some embodiments, the intermediate layer does not contain drug, and is used to separate the drug-containing layers to avoid drug cross-contamination or to achieve a pulsed drug release effect. In some embodiments, the drugs in each drug layer are the same. In some embodiments, the drugs in each drug layer are different. In some embodiments, the drug layer material is placed in a first printhead, the intermediate layer material is placed in a second printhead, and the first and second printheads alternately print the drug-containing core layer by layer.
[0142] In some embodiments, the drug unit contains multiple compartments, with a first drug-containing core and a second drug-containing core placed in the first compartment and the second compartment, respectively; the first compartment and the second compartment are placed side by side or back to back in contact.
[0143] In some embodiments, the material mixed with the drug in the drug-containing core is a thermoplastic material. In some embodiments, the thermoplastic material is a soluble and erosive material, which may be selected from any one or a combination of the following materials:
[0144] Copovidone (polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA), polyvinylpyrrolidone-polyvinyl acetate copolymer (PVP-VA) 60 / 40), crosslinked povidone, polyvinylpyrrolidone (PVP), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose or hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose phthalate (HPMCP), methylcellulose (MC), methacrylic acid copolymer, poly[butyl methacrylate, (2-dimethylaminoethyl) methyl methacrylate, methyl methacrylate] in a ratio of 1:2:1 (e.g., EUDRAGIT® E 100, EUDRAGIT® E 12,5, EUDRAGIT® E PO), poly[ethyl acrylate, methyl methacrylate] in a ratio of 2:1 (e.g., EUDRAGIT® NE 30 D, EUDRAGIT® NE 40 D, EUDRAGIT® NM 30) D) Poly[methacrylic acid, methyl methacrylate] in a 1:1 ratio (e.g., EUDRAGIT® L 100, EUDRAGIT® L 12,5, EUDRAGIT® L 12,5 P), poly[methacrylic acid, ethyl acrylate] in a 1:1 ratio (e.g., Acryl-EZE, Acryl-EZE 93A, Acryl-EZE MP, EUDRAGIT® L 30 D -55, EUDRAGIT® L 100-55, Eastacryl® 30 D, Kollicoat® MAE 30 DP, Kollicoat® MAE 100 P), and poly[methacrylic acid, methyl methacrylate] in a 1:2 ratio (e.g., EUDRAGIT® S 100, EUDRAGIT® S 12,5, EUDRAGIT® 12,5). Poly[methyl acrylate, methyl methacrylate, methacrylic acid] in a ratio of 7:3:1 (e.g., EUDRAGIT® FS 30 D), poly[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] in a ratio of 1:2:0.2 (e.g., EUDRAGIT® RL 100, EUDRAGIT® RL PO, EUDRAGIT® RL 30 D, EUDRAGIT® RL 12,5), and poly[[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] in a ratio of 1:2:0.2, and poly[ ...1% of poly[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] (e.g., EUDRAGIT® RS 100, EUDRAGIT® RS PO, EUDRAGIT® RS 30 D, EUDRAGIT® RS 12,5), polyethylene oxide (PEO), polyethylene glycol (PEG), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 57 / 30 / 13, polyethylene glycol-polyvinyl alcohol graft copolymer 25 / 75 (Kollicoat®IR), Kollicoat®IR-polyvinyl alcohol 60 / 40 (Kollicoat®Protect), polyvinyl alcohol (PVA), hydroxypropyl methylcellulose succinate or hydroxypropyl methylcellulose acetate succinate (HPMCAS), ethyl cellulose (EC), polyvinyl acetate (PVAc) and polyvinylpyrrolidone (PVP) 80 / 20, polyvinyl acetal diethylaminolactic acid ester (AEA), carboxymethyl ethyl cellulose (CMCE), carbomer, phospholipids, cyclodextrin.
[0145] In some embodiments, the material mixed with the drug in the drug-containing core may further include plasticizers and other additives. The plasticizer may be selected from any one or a combination of the following materials: triethyl citrate (TEC), vitamin E polyethylene glycol succinate (TPGS), acetic acid, acetylated triethyl citrate, tributyl citrate, acetylated tributyl citrate, polyhydroxy-15-hydroxystearate, polyoxyethylene-40 hydrogenated castor oil, polyoxyethylene ether (35) castor oil, dibutyl sebacate, diethyl phthalate, glycerin, methyl 4-hydroxybenzoate, castor oil, oleic acid, triacetic acid, polyalkylene glycol, stearic acid, palmitic acid, and glyceryl monostearate. Other additives may be any one or a combination of the following materials: acacia, alginate, alginic acid, aluminum acetate, butylparaben, butylated hydroxytoluene, citric acid, calcium carbonate, candelilla wax, croscarmellose sodium carboxymethyl cellulose, confectionery, colloidal silica, cellulose, ordinary or anhydrous calcium phosphate, carnauba wax, corn starch, calcium carboxymethyl cellulose, calcium disodium EDTA, dicalcium hydrogen phosphate dehydrate, cetylpyridine, dicalcium hydrogen phosphate, tricalcium phosphate, dicalcium hydrogen phosphate, disodium dimethyl silicate, sodium erythritol, EDTA, gelatin, glyceryl oleate, iron oxide, ferric oxide, iron oxide yellow Iron oxide red, lactose (hydrated, anhydrous, monohydrate or spray-dried), microcrystalline cellulose, magnesium carbonate, magnesium oxide, methylparaben, polysorbate 80, propylparaben, potassium bicarbonate, potassium sorbate, potato starch, phosphoric acid, polyoxyethylene (40) stearate, sodium arc glycolate, pregelatinized starch, sodium crosslinked cellulose, sodium dodecyl sulfate, starch, silicon dioxide, sodium benzoate, sucrose, sorbic acid, sodium carbonate, sodium saccharin, sodium alginate, silicone, dehydrated sorbitol monooleate, sodium chloride, sodium metabisulfite, dehydrated sodium citrate, sodium starch, sodium carboxymethyl cellulose, succinic acid, sodium propionate, titanium dioxide, talc, magnesium stearate, calcium stearate.
[0146] Plug or middle layer
[0147] In some embodiments, the pharmaceutical unit described herein further includes one or more stoppers or intermediate layers for achieving delayed or pulsed release of the drug. In some embodiments, the stopper or intermediate layer is not mixed with the drug. In some embodiments, the stopper or intermediate layer is in direct contact with the drug-containing layer. In some embodiments, the stopper or intermediate layer is in direct contact with the shell. In some embodiments, the stopper is in direct contact with both the shell and the drug-containing layer. In some embodiments, the intermediate layer is in direct contact with both the shell and the drug-containing layer. In some embodiments, the stopper is located above the drug-containing layer and, upon administration to the human body, is the first to come into contact with and dissolve in gastric juices. In some embodiments, the intermediate layer is located between the plurality of drug-containing layers.
[0148] In some embodiments, the stopper or interlayer allows for delayed or pulsed release of the drug from the drug unit. In some embodiments, the time for complete dissolution of the stopper or interlayer is from about 1 minute to about 12 hours, such as any one of about 1 minute to 10 minutes, about 10 minutes to about 30 minutes, about 30 minutes to about 1 hour, about 1 hour to about 3 hours, about 3 hours to about 6 hours, about 6 hours to about 9 hours, or about 9 hours to about 12 hours. In some embodiments, the interlayer may reduce or prevent interference between two or more drug-containing layers in contact with the interlayer.
[0149] In some embodiments, the dissolution rate (or erosion rate) of the intermediate layer is from about 0.1 mm / hour to about 50 mm / hour. In some embodiments, the dissolution rate (or erosion rate) of the intermediate layer is at least about 0.1 mm / hour, such as at least about 1 mm / hour, 5 mm / hour, 10 mm / hour, 20 mm / hour, 30 mm / hour, or 40 mm / hour. In some embodiments, the dissolution rate (or erosion rate) of the intermediate layer is less than about 50 mm / hour, such as less than about 40 mm / hour, 30 mm / hour, 20 mm / hour, 10 mm / hour, 5 mm / hour, or 1 mm / hour.
[0150] In some embodiments, an intermediate layer is stacked on top of a drug-containing layer, wherein the intermediate layer has an upper surface and a lower surface, wherein the drug-containing layer has an upper surface and a lower surface, and wherein the shell is in direct contact with both the intermediate layer and the drug-containing layer. In some embodiments, the drug-containing layer is stacked on top of the intermediate layer. In some embodiments, the shell exposes the upper surface of the intermediate layer.
[0151] In some embodiments, the stopper or intermediate layer has a slower dissolution rate compared to the drug-containing layer. In some embodiments, the stopper or intermediate layer has a faster dissolution rate compared to the drug-containing layer. In some embodiments, the stopper or intermediate layer has the same dissolution rate compared to the drug-containing layer.
[0152] In some embodiments, the plug or intermediate layer is made of a thermoplastic material. In some embodiments, the thermoplastic material of the stopper or intermediate layer is an abrasive material. In some embodiments, the abrasive material is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 57 / 30 / 13, vinyl pyrrolidone-vinyl acetate copolymer (PVP-VA), vinyl pyrrolidone-vinyl acetate copolymer (PVP-VA) 60 / 40, polyvinyl pyrrolidone (PVP), polyvinyl acetate (PVAc), and polyvinyl pyrrolidone (PVP) 80 / 20, vinyl pyrrolidone-vinyl acetate copolymer (VA64), polyethylene glycol-polyvinyl alcohol graft copolymer 25 / 75, kollicoat IR-polyvinyl alcohol 60 / 40, polyvinyl alcohol (PVA or PV-OH), poly(vinyl acetate) (PVAc), and poly[butyl methacrylate, (2-dimethylaminoethyl) methyl methacrylate, methyl methacrylate] in a ratio of 1:2:1 (e.g., EUDRAGIT® E EUDRAGIT®E 12,5, EUDRAGIT®E PO), poly[ethyl acrylate, methyl methacrylate] in a 2:1 ratio (e.g., EUDRAGIT®NE 30 D, EUDRAGIT®NE 40 D, EUDRAGIT®NM 30 D), poly[methacrylic acid, methyl methacrylate] in a 1:1 ratio (e.g., EUDRAGIT®L 100, EUDRAGIT®L 12,5, EUDRAGIT®L 12,5 P), poly[methacrylic acid, ethyl acrylate] in a 1:1 ratio (e.g., Acryl-EZE, Acryl-EZE 93A, Acryl-EZE MP, EUDRAGIT®L 30 D -55, EUDRAGIT®L 100-55, Eastacryl®30 D, Kollicoat®MAE 30 DP, Kollicoat®MAE 100) EUDRAGIT® S 100, EUDRAGIT® S 12,5, EUDRAGIT® 12,5 P, in a 1:2 ratio; EUDRAGIT® methyl methacrylate, methyl methacrylate, methacrylic acid, in a 7:3:1 ratio (e.g., EUDRAGIT® FS 30 D); EUDRAGIT® ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate, in a 1:2:0.2 ratio (e.g., EUDRAGIT® RL 100, EUDRAGIT® RL PO, EUDRAGIT® RL 30 D, EUDRAGIT® RL 12,5); and EUDRAGIT® RL 12,5 P, in a 1:2:0.2 ratio.1% of poly[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] (e.g., EUDRAGIT® RS 100, EUDRAGIT® RS PO, EUDRAGIT® RS 30 D, EUDRAGIT® RS 12,5), polyethylene oxide (PEO), polyethylene glycol (PEG), hyperbranched polyamide, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose or hydroxypropyl methylcellulose (HMPC), hydroxypropyl methylcellulose acetate succinate or hydroxypropyl methylcellulose succinate (HPMCAS), lactide-glycolic acid copolymer (PLGA), carbomer, ethylene-vinyl acetate copolymer, cellulose or cellulose derivatives, hydroxypropyl cellulose (HPC), polyoxyethylene 40 hydrogenated castor oil, methylcellulose (MC), ethyl cellulose The following are included in the list of ingredients: EC, poloxamer, hydroxypropyl methylcellulose phthalate (HPMCP), poloxamer, hydrogenated castor oil and soybean oil, glyceryl palmitate stearate, carnauba wax, polyglycolic acid (PGA), cellulose acetate butyrate (CAB), colloidal silica, sugars, glucose, polyvinyl acetate phthalate (PVAP), waxes, beeswax, hydrogels, gelatin, hydrogenated vegetable oils, polyvinyl acetate diethylamide (AEA), paraffin wax, shellac, sodium alginate, cellulose acetate phthalate (CAP), fatty oils, gum arabic, and xanthan gum, or one or a combination thereof.
[0153] In some embodiments, the thermoplastic material is mixed with a plasticizer or other additives. In some embodiments, the plasticizer or other additives are selected from triethyl citrate (TEC), vitamin E polyethylene glycol succinate (TPGS), acetic acid, acetylated triethyl citrate, tributyl citrate, acetylated tributyl citrate, polyhydroxy 15-hydroxystearate, polyoxyethylene-40 hydrogenated castor oil, polyoxyethylene ether (35) castor oil, polyoxyethylene-polyoxypropylene block copolymer, dibutyl sebate, diethyl phthalate, glycerin, methyl 4-hydroxybenzoate, castor oil, oleic acid, triacetic acid, polyalkylene glycol, hydroxystearate, Polyethylene glycol (e.g., PEG400), polyethylene glycol cetearyl ether 12, polyethylene glycol 20 cetearyl ether, polysorbate 20, polysorbate 60, polysorbate 80, dibutyl sebacate, diethyl phthalate, glycerol, methyl 4-hydroxybenzoate, glycerin, castor oil, oleic acid, glyceryl triacetate, polyalkylene glycol, glyceryl monostearate, stearic acid, acacia, alginate, alginic acid, aluminum acetate, butylparaben, butylated hydroxytoluene, citric acid, palmitic acid, calcium carbonate, candelilla wax, croscarmellose. Sodium, confectionery sugars, colloidal silicon dioxide, cellulose, ordinary or anhydrous calcium phosphate, carnauba wax, corn starch, calcium carboxymethyl cellulose, calcium disodium EDTA, dicalcium hydrogen phosphate dehydrate, cetylpyridine, dicalcium hydrogen phosphate, tricalcium phosphate, dicalcium hydrogen phosphate, disodium hydrogen phosphate, dimethyl silicate oil, sodium erythritol, EDTA, gelatin, glyceryl oleate, iron oxide, ferric oxide, iron oxide yellow, iron oxide red, lactose (hydrated, anhydrous, monohydrate, or spray-dried), microcrystalline cellulose, magnesium carbonate, magnesium oxide, p-hydroxybenzene Methyl formate, polysorbate 80, propylparaben, potassium bicarbonate, potassium sorbate, potato starch, phosphoric acid, polyoxyethylene (40) stearate, sodium arc glycolate, pregelatinized starch, sodium crosslinked cellulose, sodium dodecyl sulfate, starch, silicon dioxide, sodium benzoate, sucrose, sorbic acid, sodium carbonate, sodium saccharin, sodium alginate, silicone, dehydrated sorbitol monooleate, sodium chloride, sodium metabisulfite, dehydrated sodium citrate, sodium starch, sodium carboxymethyl cellulose, succinic acid, sodium propionate, titanium dioxide, talc, magnesium stearate, calcium stearate, or a combination thereof.
[0154] In some embodiments, the plug or intermediate layer is printed using a hot melt extruded material.
[0155] Shell
[0156] In some embodiments, the drug unit includes a shell. In some embodiments, the shell partially surrounds the drug-containing core.
[0157] In some embodiments, the shell is not mixed with the drug. In some embodiments, the shell is mixed with different drugs.
[0158] In some embodiments, the shell is non-corrosive. In some embodiments, the shell has a slower rate of erosion compared to the ER layer. In some embodiments, the shell is substantially eroded only after all the drug in the ER layer has been substantially released therefrom. In some embodiments, the shell is substantially non-corrosive for at least about 6 hours (such as at least about 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, 22, 22, 24, 30, 36, 48, or 72 hours) after administration of a dose unit to an individual. In some embodiments, the shell comprises a pH-sensitive material, such as a material that erodes within a specific pH range.
[0159] In some embodiments, the shell is impermeable, such as impermeable to water or gastrointestinal fluids. In some embodiments, the shell is substantially impermeable.
[0160] In some embodiments, the material of the housing portion may include a thermoplastic polymer, which may be any one or a combination of the following materials: cellulose acetate phthalate (CAP), poly[butyl methacrylate, (2-dimethylaminoethyl) methyl methacrylate, methyl methacrylate] in a 1:2:1 ratio (e.g., EUDRAGIT® E 100, EUDRAGIT® E 12,5, EUDRAGIT® E PO), poly[ethyl acrylate, methyl methacrylate] in a 2:1 ratio (e.g., EUDRAGIT® NE 30 D, EUDRAGIT® NE 40 D, EUDRAGIT® NM 30 D), and poly[methacrylic acid, methyl methacrylate] in a 1:1 ratio (e.g., EUDRAGIT® L 100, EUDRAGIT® L 12,5, EUDRAGIT® L 12,5). Poly[methacrylic acid, ethyl acrylate] in a 1:1 ratio (e.g., Acryl-EZE, Acryl-EZE 93A, Acryl-EZE MP, EUDRAGIT®L 30 D -55, EUDRAGIT®L 100-55, Eastacryl®30 D, Kollicoat®MAE 30 DP, Kollicoat®MAE 100 P), poly[methacrylic acid, methyl methacrylate] in a 1:2 ratio (e.g., EUDRAGIT®S 100, EUDRAGIT®S 12,5, EUDRAGIT®12,5 P), poly[methyl acrylate, methyl methacrylate, methacrylic acid] in a 7:3:1 ratio (e.g., EUDRAGIT®FS 30 D), and poly[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] in a 1:2:0.2 ratio (e.g., EUDRAGIT®RL). EUDRAGIT® RL PO, EUDRAGIT® RL 30 D, EUDRAGIT® RL 12,5), in a ratio of 1:2:0.1, contains poly[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] (e.g., EUDRAGIT® RS 100, EUDRAGIT® RS PO, EUDRAGIT® RS 30 D, EUDRAGIT® RS 12,5), polylactic acid-glycolic acid copolymer (PLGA), ethylene-vinyl acetate copolymer (EVA), polyethylene (PE), polycaprolactone (PCL), polylactic acid (PLA), cellulose acetate butyrate (CAB), cellulose acetate (CA), polyvinyl acetate (PVAc), polyvinyl acetal diethylaminoacetate (AEA), ethyl cellulose (EC), carboxymethyl ethyl cellulose (CMCE), carbomer, phospholipids, and cyclodextrin.
[0161] In some embodiments, the material of the shell portion may further include an expandable material, which includes any one or a combination of the following materials: high molecular weight hydroxypropyl cellulose (HPC), high molecular weight hydroxypropyl methylcellulose or hydroxypropyl methylcellulose (HPMC), methylcellulose (MC), high molecular weight polyethylene oxide (PEO), high molecular weight polyvinyl alcohol (PVA), polyvinyl acetate (PVAc) and polyvinylpyrrolidone (PVP) 80 / 20, poly[butyl methacrylate, (2-dimethylaminoethyl) methyl methacrylate, methyl methacrylate] in a ratio of 1:2:1 (e.g., EUDRAGIT® E 100, EUDRAGIT® E 12,5, EUDRAGIT® E PO), and poly[ethyl acrylate, methyl methacrylate] in a ratio of 2:1 (e.g., EUDRAGIT® NE 30 D, EUDRAGIT® NE 40 D, EUDRAGIT® NM 30). D) Poly[methacrylic acid, methyl methacrylate] in a 1:1 ratio (e.g., EUDRAGIT® L 100, EUDRAGIT® L 12,5, EUDRAGIT® L 12,5 P), poly[methacrylic acid, ethyl acrylate] in a 1:1 ratio (e.g., Acryl-EZE, Acryl-EZE 93A, Acryl-EZE MP, EUDRAGIT® L 30 D -55, EUDRAGIT® L 100-55, Eastacryl® 30 D, Kollicoat® MAE 30 DP, Kollicoat® MAE 100 P), and poly[methacrylic acid, methyl methacrylate] in a 1:2 ratio (e.g., EUDRAGIT® S 100, EUDRAGIT® S 12,5, EUDRAGIT® 12,5). Poly[methyl acrylate, methyl methacrylate, methacrylic acid] in a ratio of 7:3:1 (e.g., EUDRAGIT® FS 30 D), poly[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] in a ratio of 1:2:0.2 (e.g., EUDRAGIT® RL 100, EUDRAGIT® RL PO, EUDRAGIT® RL 30 D, EUDRAGIT® RL 12,5), poly[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] in a ratio of 1:2:0.1 (e.g., EUDRAGIT® RS 100, EUDRAGIT® RS PO, EUDRAGIT® RS 30 D, EUDRAGIT® RS 12,5), hydroxypropyl methylcellulose succinate (HPMCAS), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetal diethylaminolactic acid (AEA), or combinations thereof.
[0162] In some embodiments, shell dissolution is pH-dependent. In some embodiments, shell dissolution occurs at pH values above about 5.5 to about 7. In some embodiments, dissolution occurs at pH values above about 5.5, about 6, about 6.5, or about 7. In some embodiments, the shell comprises an enteric material.
[0163] In some embodiments, the shell is printed by hot melt extrusion of shell material.
[0164] The "pharmaceutical unit" structures and materials described herein may be any pharmaceutical unit structure, compartment structure, intermediate layer structure, dosing unit structure, or combination thereof described in U.S. patents with patent numbers US10258575 and US10363220, U.S. patent applications with application numbers US2019192440, US2019321299, and US2020315971, and international patent applications with publication numbers WO2019137200, WO2016192680, WO2017193099, WO2018137686, and WO2019137199 and their corresponding national phase patent applications. The full text of the aforementioned patents and patent applications is incorporated herein by reference.
[0165] It should be noted that in some embodiments, the drug unit shell portion can be made of the same material as the unfolding component, thereby effectively improving the manufacturing efficiency of the drug dosage form.
[0166] The term “medicine” as used herein includes, but is not limited to, drugs, prodrugs, biological agents and any other substances that can be administered to suppress disease or produce beneficial health effects.
[0167] In some embodiments, the drug in pharmaceutical unit 102 is a drug administered via the gastrointestinal tract, and the drug may be one or a combination of the following: statins, such as rosuvastatin; nonsteroidal anti-inflammatory drugs (NSAIDs), such as meloxicam; blood thinners, such as clopidogrel; analgesics, such as buprenorphine; opioid antagonists, such as naloxone; antiasthmatics, such as montelukast; steroids, such as prednisone; antipsychotics, such as aripiprazole and risperidone; cardiac glycosides, such as digoxin; alpha blockers, such as tamsulosin; cholesterol absorption inhibitors, such as ezetimibe; antihistamines, such as loratadine and cetirizine; proton pump inhibitors, such as omeprazole; antiviral agents, such as entecavir; antibiotics, such as doxycycline, ciprofloxacin, and azithromycin; substance abuse treatment agents, such as methadone and varenicline; contraceptives; stimulants, such as caffeine; and antigout treatment agents, such as colchicine. In some embodiments, the pharmaceutical base may be nutrients, including but not limited to: folic acid, calcium, iodine, iron, zinc, nicotinic acid, vitamin C, vitamin D, biotin, plant extracts, plant hormones, and other vitamins or minerals.
[0168] Retaining component
[0169] A retaining member is connected to at least one unfolding member, and a restraining force is applied to the at least one unfolding member to keep the unfolding member in a contracted shape, wherein the retaining member comprises a water-soluble material and is configured to remove the restraining force on the unfolding member when the water-soluble material dissolves, thereby allowing at least one unfolding member to change from a contracted shape to an unfolded shape to achieve effective retention in the gastrointestinal tract. In some embodiments, particularly where the restraining force is applied from the outside of the unfolding member, the retaining member should generally have high rigidity in order to achieve the restraining force on the unfolding member.
[0170] In some embodiments, the retaining component material is a thermoplastic material. In some embodiments, the water-soluble, fast-release thermoplastic material is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 57 / 30 / 13, vinyl pyrrolidone-vinyl acetate copolymer (PVP-VA), vinyl pyrrolidone-vinyl acetate copolymer (PVP-VA) 60 / 40, polyvinyl pyrrolidone (PVP), polyvinyl acetate (PVAc), and polyvinyl pyrrolidone (PVP) 80 / 20, vinyl pyrrolidone-vinyl acetate copolymer (VA64), polyethylene glycol-polyvinyl alcohol graft copolymer 25 / 75, kollicoat One or a combination of IR-polyvinyl alcohol 60 / 40, polyvinyl alcohol (PVA or PV-OH), polyethylene oxide (PEO), polyethylene glycol (PEG), cellulose or cellulose derivatives, hydroxypropyl methylcellulose acetate succinate or hydroxypropyl methylcellulose succinate (HPMCAS), carbomer, hydroxypropyl cellulose (HPC), poloxamer, hydroxypropyl methylcellulose phthalate (HPMCP), poloxamer, polyglycolic acid (PGA), sugars, glucose, hydrogels, gelatin, sodium alginate, gum arabic, and xanthan gum.
[0171] In some embodiments, the retaining component material further includes a plasticizer or other additive selected from triethyl citrate (TEC), vitamin E polyethylene glycol succinate (TPGS), acetic acid, acetylated triethyl citrate, tributyl citrate, acetylated tributyl citrate, polyhydroxy 15-hydroxystearate, polyoxyethylene-40 hydrogenated castor oil, polyoxyethylene ether (35) castor oil, polyoxyethylene-polyoxypropylene block copolymer, dibutyl sebacate, diethyl phthalate, glycerin, methyl 4-hydroxybenzoate, castor oil, oleic acid Triacetin, polyalkylene glycol, hydroxystearate, polyethylene glycol (e.g., PEG400), polyethylene glycol cetearyl ether 12, polyethylene glycol 20 cetearyl ether, polysorbate 20, polysorbate 60, polysorbate 80, dibutyl sebacate, diethyl phthalate, glycerol, methyl 4-hydroxybenzoate, glycerin, castor oil, oleic acid, glyceryl triacetate, polyalkylene glycol, glyceryl monostearate, stearic acid, acacia, alginate, alginic acid, aluminum acetate, butyl paraben, butylated hydroxytoluene, citric acid, palmitic acid, calcium carbonate, Candelilla wax, croscarmellose sodium carboxymethyl cellulose, confectionery, colloidal silica, cellulose, ordinary or anhydrous calcium phosphate, carnauba wax, corn starch, calcium carboxymethyl cellulose, calcium disodium EDTA, dicalcium hydrogen phosphate dehydrate, cetylpyridine, dicalcium hydrogen phosphate, tricalcium phosphate, dicalcium hydrogen phosphate, disodium hydrogen phosphate, dimethyl silicate oil, sodium erythritol, EDTA, gelatin, glyceryl oleate, iron oxide, ferric oxide, iron oxide yellow, iron oxide red, lactose (hydrated, anhydrous, monohydrate or spray-dried), microcrystalline cellulose, magnesium carbonate, oxygen Magnesium hydroxide, methylparaben, polysorbate 80, propylparaben, potassium bicarbonate, potassium sorbate, potato starch, phosphoric acid, polyoxyethylene (40) stearate, sodium arc glycolate, pregelatinized starch, sodium crosslinked cellulose, sodium dodecyl sulfate, starch, silicon dioxide, sodium benzoate, sucrose, sorbic acid, sodium carbonate, sodium saccharin, sodium alginate, silicone, dehydrated sorbitol monooleate, sodium chloride, sodium metabisulfite, dehydrated sodium citrate, sodium starch, sodium carboxymethyl cellulose, succinic acid, sodium propionate, titanium dioxide, talc, magnesium stearate, calcium stearate, or a combination thereof.
[0172] In other embodiments, the retaining member may be located at least partially between the deploying member and the drug unit to bond the two together, thereby holding the deploying member in a contracted shape; in this case, the retaining member may be partially exposed from the surface of the drug dosage form, thereby allowing the liquid to dissolve the retaining member and ultimately remove the bond between the deploying member and the drug unit.
[0173] In some embodiments, the retaining member at least partially covers the drug unit and at least one unfolding member such that at least one unfolding member is in a contracted shape.
[0174] Figures 9 and 10 show top views of drug dosage forms 500 and 600 according to embodiments of the present invention. Drug dosage forms 500 and 600 have structures generally similar to the drug unit and unfolding member of drug dosage form 100 shown in Figures 1 and 2. As shown in Figure 9, an elongated retaining member 503 is located above and connected to both the unfolding member 501 and the drug unit 502, thereby holding them in a contracted shape where the unfolding member 501 fits around the outer peripheral wall of the drug unit 502, as shown. As shown in Figure 10, the retaining member 503 may also be a plurality of point-block structures located above the unfolding member 501 and the drug unit 502 and discretely attached along the gap where they fit together. In some embodiments, to provide a reliable restraining effect, the retaining member 503 may also be an annular structure attached above the joint gap between the unfolding member 501 and the drug unit 502.
[0175] Figures 13 to 16 show a top view and a front view of a drug dosage form 800 in its unfolded shape after the retaining member is removed, as well as a front view and a cross-sectional top view of the drug dosage form according to an embodiment of the present invention. As shown, when in the contracted shape, the unfolding member 801 folds upward to fit and cover a portion of the outer peripheral sidewall of the drug unit 802. The retaining member not only covers other portions of the outer peripheral sidewall of the drug unit 802, but also covers the upper part connecting the unfolding member 801 and the drug unit 802, thereby providing effective and reliable restraint. In some other embodiments, the retaining member 803 may also only cover the outer peripheral sidewall of the drug unit 802 without covering the unfolding member 801 and the upper or lower part of the drug unit 802.
[0176] Figures 17 to 20 show perspective views of a pharmaceutical dosage form 900 in an expanded shape and a contracted shape after the retaining member is removed, according to an embodiment of the present invention, as well as perspective and cross-sectional views of the pharmaceutical dosage form 900. As shown in Figures 17 and 18, the expanded member 901 of the pharmaceutical dosage form 900 is a strip-shaped member extending from the outer peripheral wall of the pharmaceutical unit 902. When in the contracted shape, it wraps around the outer peripheral sidewall of the pharmaceutical unit 902 and partially covers the outer peripheral sidewall of the pharmaceutical unit 902. As shown in Figures 19 and 20, the retaining member 903 covers other parts of the outer peripheral sidewall of the pharmaceutical unit 902 and covers the upper part and outer peripheral sidewall of the expanded member 901 in the contracted shape. The structure in Embodiment 1000 shown in Figure 21 is generally similar to that in Embodiment 900, wherein the unfolding member 1001, which is wound around the drug unit 1002, generally covers the outer peripheral sidewall of the cylindrical drug unit 1002, and the retaining member 1003 completely covers the upper wall and outer peripheral sidewall of the structure formed by the drug unit 1002 and the unfolding member 1001 in its contracted shape. In other embodiments, the retaining member 1003 may also completely cover the overall structure formed by the drug unit 1002 and the unfolding member 1001 in its contracted shape.
[0177] Figures 22 to 25 show perspective views of a drug dosage form 1100 in an expanded shape and a contracted shape after the retaining member is removed, according to an embodiment of the present invention, as well as a top view and a cross-sectional view of the drug dosage form 1100. As shown in Figures 22 and 23, the expanded member 1101 of the drug dosage form 1100 is two strip-shaped members on the outer peripheral wall of the drug unit 1102. When in the contracted shape, the two expanded members 1101 are respectively rolled around the outer peripheral sidewall of the drug unit 1102 and partially cover the outer peripheral sidewall of the drug unit 1102. As shown in Figures 24 and 25, the retaining member 1103 covers other parts of the outer peripheral sidewall of the drug unit 1102 and covers the upper part and outer peripheral sidewall of the two expanded members 1101 in the contracted shape. In other embodiments, the retaining member 1103 may also completely cover the structure formed by the drug unit 1102 and the expanded member 1101 in the contracted shape, or cover the upper wall and outer peripheral sidewall of the structure.
[0178] In some embodiments, the drug unit may include a drug-containing portion and a drug-free portion, and the drug-containing portion is configured to be formed independently of the other portions.
[0179] The structure of the unfolding member 1201, drug unit 1204, and retaining member 1203 of the drug dosage form 1200 shown in Figure 26 is generally similar to that of Embodiment 1. The difference is that a floating member 1207 is attached to the drug unit 1204. The drug unit 1204 defines three compartments 1206, each of which can be filled with the drug-containing core material as shown above, such as a drug or a mixture of a drug with a soluble material or other excipients. The shell material of the drug unit 1204 can be the same as that used for the upper shell portion, and a plug structure 1205 as described above is provided on its upper part to dissolve in gastrointestinal fluid, thereby exposing the drug in the compartment to the gastrointestinal fluid. In some embodiments, the three plug structures 1205 shown in Figure 26 can be made of materials with different dissolution rates or have different dimensions (e.g., thickness, size, etc.) to achieve pulsed release of the drug-containing core material within the compartment 1206. In some embodiments, the floating member 1207 can be configured as a cavity, honeycomb structure, or scaffold structure to provide buoyancy for better retention. The aforementioned drug unit 1204 can be formed independently of other parts by 3D printing or additive manufacturing. Although Figure 26 shows a specific structure of the drug unit 1204, it can also be any available 3D-printed pharmaceutical dosage form construction. Because the drug-containing portion can be printed independently of other structures—for example, printing the portion below the drug unit 1204 first, followed by printing the drug unit 1204 independently—the drug unit 1204 can employ any existing procedure, method, or structural design for manufacturing pharmaceutical dosage forms by printing or additive manufacturing without further modification to meet gastric retention requirements, thereby reducing the research and development and manufacturing costs of the specific product.
[0180] For example, in some embodiments, a single compartment of the drug unit 1204 may contain multiple drug layers formed of soluble materials with different dissolution rates. Different combinations of their stacking positions, shapes, and sizes can achieve target release profiles for one or more drugs. In other embodiments, the number of compartments can be any number of other materials, such as 1, 2, 4, 5, 6, etc. In some embodiments, multiple compartments may be filled with the same or different drug materials, and they may have different positional relationships, such as stacking, staggering, etc. In other embodiments, some compartments may be empty, thereby providing additional buoyancy to the drug dosage form to better achieve a retention effect.
[0181] Although the drug unit 1204 shown in the figure is connected to the floating member 1207 and the holding member 1203, in some other embodiments, the drug unit 1204 may also be connected to the unfolding member 1201 at the same time, or only to either the floating member 1207 or the unfolding member 1201, so that the drug unit 1204 can be effectively retained in the gastrointestinal space with the assistance of the unfolding member 1201 after unfolding.
[0182] Figures 27 and 28 show a top view and a cross-sectional view of a drug dosage form 1300 according to an embodiment of the present invention. The drug dosage form 1300 has a configuration similar to that shown in Figures 22 and 23, and will not be described in detail here. As shown in Figures 27 and 28, when in a contracted shape, the unfolding member 1301 generally covers the lower half of the sidewall of the drug unit 1302, while the retaining member 1303 covers the upper half of the outer peripheral sidewall of the drug unit 1302 and is simultaneously connected to the upper side of the unfolding member 1301 below it, thereby holding the unfolding member 1301 in a contracted shape. This configuration can minimize the size of the final drug dosage form and reduce costs while maintaining the restraining effect on the unfolding member.
[0183] The structure of the unfolding member 1401, the floating member 1407, and the retaining member 1403 of the drug dosage form 1400 shown in Figure 29 is generally similar to that of Example 3. The difference is that the drug unit shown consists of a shell 1404, a drug-containing layer 1406, and a stopper or intermediate layer 1405. The drug unit defines two stacked compartments 1406, and the drug layer or drug material that can be filled in the compartments is similar to that of compartment 1206, and will not be described again here. A cap structure 1405 similar to the cap structure 1205 on the drug dosage form 1200 is provided on the upper part of the compartment. Similar to the structure of the drug-containing part 1204 shown in Figure 28 above, the drug unit of the drug dosage form 1400 shown in Figure 29 can also be formed independently of other parts. Therefore, it can also be designed or manufactured using existing mature 3D printing drug dosage form design or manufacturing processes.
[0184] In some embodiments, a retaining member is disposed between and connected to the drug unit and the deploying member, such that the deploying member is in a contracted shape. Specifically, in some embodiments, there are gaps between the deploying member in its contracted shape and the drug unit, and the retaining member is used to at least partially fill these gaps, thereby causing the deploying member to be in a contracted shape. In some embodiments, the drug dosage form includes a plurality of deploying members, and the retaining member connects at least two deploying members such that at least two deploying members are in a contracted shape.
[0185] Figure 12 shows a top view of a pharmaceutical dosage form 700 according to an embodiment of the present invention. Figure 11 shows a top view of the pharmaceutical dosage form 700 with the unfolding member 701 in an unfolded shape after the retaining member is removed. The structure of the pharmaceutical dosage form 700 in the unfolded shape shown in Figure 11 is generally similar to that of the embodiment shown in Figure 1, having two unfolding members 701 extending from the cylindrical drug unit 702. The retaining member 703 of the pharmaceutical dosage form 700 shown in Figure 12 includes multiple parts, and the ends of the two unfolding members 701 away from the drug unit 702 are connected to each other by retaining members 731 to constrain the two unfolding members 701 in a contracted state. In addition, the retaining member 703 of the pharmaceutical dosage form 700 also includes two retaining members 732 as shown, which are disposed between the unfolding member 701 and the drug unit 702 to assist in holding the unfolding member 701 in a contracted shape. It is understood that the retaining member 732 may be exposed from at least a portion of the outer surface of the drug dosage form 700, thereby allowing the liquid to contact the retaining member 732 to gradually dissolve the retaining member 732 when the drug dosage form 700 is placed in an aqueous solution.
[0186] It should be noted that although FIG12 shows that the retaining member 703 includes two types of retaining members 731 and 732, in some embodiments, the retaining member may include only one of them. In other embodiments, the retaining member 703 may also adopt a combination of the several retaining member arrangements described above.
[0187] Drug Formulation II
[0188] The present invention also provides another pharmaceutical dosage form. This pharmaceutical dosage form includes a pharmaceutical unit containing a drug and a retaining member. At least a portion of the pharmaceutical unit is curved or folded, and the retaining member is connected to the pharmaceutical unit and applies a restraining force to the pharmaceutical unit so that at least a portion of the pharmaceutical unit retains its curved or folded shape. The retaining member comprises a water-soluble material and is configured to remove the restraining force on the pharmaceutical unit when the water-soluble material dissolves, thereby allowing at least a portion of the pharmaceutical unit to unfold from its curved or folded shape. In some embodiments, the pharmaceutical dosage form may be formed by 3D printing.
[0189] This drug formulation does not require a complex unfolding component structure. After the component is at least partially dissolved in the gastrointestinal fluid, the drug unit itself can unfold from a curved or folded shape to extend and expand its overall size, thereby achieving retention in the stomach or other parts of the upper digestive tract, so as to prolong the retention time of the drug at the site of action, reduce the number of administrations, and improve bioavailability.
[0190] In some embodiments, the drug unit of the drug dosage form may be integrally elastic or include an elastic portion as described in Figures 1 and 2 above. Under the action of the elastic portion, the drug unit quickly returns to an unbent or folded state after losing the constraint of the holding member, thereby achieving a retention effect. In other embodiments, the drug unit of the drug dosage form may not include an elastic portion or elastic material. When the holding member is eroded, the drug unit naturally unfolds into an unbent or folded shape under the external force of gastrointestinal fluid or gastric and intestinal tissues. In still other embodiments, the drug unit may be configured to have different thicknesses, thereby forming at least one thickness-reduced portion as described above. Since no elastic material is used in the above structures, when the drug dosage form is printed using 3D printing technology, the drug unit can be directly printed in a shrunken shape, thereby effectively improving printing efficiency.
[0191] FIG30 shows a top view of a pharmaceutical dosage form 1500 according to an embodiment of the present invention. FIG31 shows a perspective view of the pharmaceutical dosage form 1500 shown in FIG30 unfolded into a strip shape after the retaining member is removed. As shown in FIG30 and 31, the pharmaceutical dosage form 1500 includes a pharmaceutical unit 1502 and a retaining member 1503. The pharmaceutical unit 1502 has a spiral shape with a radius of curvature that gradually increases from the inside to the outside, while the retaining member 1503 in the white area fills the gaps in the spiral shape of the pharmaceutical unit 1502.
[0192] Although the retaining member 1503, as shown in the figure, fills the entire gap of the spiral shape of the drug unit 1502, in other embodiments, the retaining member 1503 may only fill part of the gap, thereby reducing costs and improving production efficiency. Although the drug unit 1502, as shown in Figure 31, is strip-shaped when fully unfolded, in some embodiments, the drug unit 1502 may also be constructed as an elongated member of other shapes that are easy to bend or fold, such as rope-like, rod-like, or cuboid. Furthermore, although the drug unit 1502, as shown in the figure, is coiled into a spiral shape, in other embodiments, the drug unit 1502 may be folded into any other shape that effectively reduces the extension length of the drug unit in a certain direction, such as an S-shaped, figure-eight-shaped, or Z-shaped continuous folding shape, etc.
[0193] Referring again to Figures 30 and 31, the drug unit 1502 specifically includes a housing portion 1521 and a drug-containing portion 1522 embedded in a groove formed on the housing. The drug-containing portion 1522 may be composed of a drug, pharmaceutical excipients, and a soluble material. In some embodiments, the drug-containing portion 1522 may be configured as a multi-layered drug-containing portion as described above, composed of different soluble materials and / or drugs.
[0194] In some embodiments, the housing portion 1521 is made of a hydrophobic or pH-dependent material, thereby providing buoyancy or surface tension to the drug unit in gastric fluid for better retention. In other embodiments, the outer surface of the housing portion 1521 is provided with a hydrophobic or pH-dependent material.Specifically, the aforementioned hydrophobic or pH-dependent materials may be selected from one or more of the following pharmaceutical-grade polymers: cellulose acetate phthalate (CAP), poly[butyl methacrylate, (2-dimethylaminoethyl) methyl methacrylate, methyl methacrylate] in a 1:2:1 ratio (e.g., EUDRAGIT® E 100, EUDRAGIT® E 12,5, EUDRAGIT® E PO), poly[ethyl acrylate, methyl methacrylate] in a 2:1 ratio (e.g., EUDRAGIT® NE 30 D, EUDRAGIT® NE 40 D, EUDRAGIT® NM 30 D), poly[methacrylic acid, methyl methacrylate] in a 1:1 ratio (e.g., EUDRAGIT® L 100, EUDRAGIT® L 12,5, EUDRAGIT® L 12,5 P), and poly[methacrylic acid, ethyl acrylate] in a 1:1 ratio (e.g., Acryl-EZE, Acryl-EZE). 93A, Acryl-EZE MP, EUDRAGIT®L 30 D -55, EUDRAGIT®L 100-55, Eastacryl®30 D, Kollicoat®MAE 30 DP, Kollicoat®MAE 100 P), poly[methacrylic acid, methyl methacrylate] in a 1:2 ratio (e.g., EUDRAGIT®S 100, EUDRAGIT®S 12,5, EUDRAGIT®12,5 P), poly[methyl acrylate, methyl methacrylate, methacrylic acid] in a 7:3:1 ratio (e.g., EUDRAGIT®FS 30 D), and poly[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] in a 1:2:0.2 ratio (e.g., EUDRAGIT®RL 100, EUDRAGIT®RL PO, EUDRAGIT®RL 30 D, EUDRAGIT®RL 12,5), in a ratio of 1:2:0.1, poly[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] (e.g., EUDRAGIT® RS 100, EUDRAGIT® RS PO, EUDRAGIT® RS 30 D, EUDRAGIT® RS 12,5), polylactic acid-glycolic acid copolymer (PLGA), ethylene-vinyl acetate copolymer (EVA), polyethylene (PE), polycaprolactone (PCL), polylactic acid (PLA), cellulose acetate butyrate (CAB), cellulose acetate (CA), polyvinyl acetate (PVAc), polyvinyl acetal diethylaminoacetate (AEA), ethyl cellulose (EC), carboxymethyl ethyl cellulose (CMCE), carbomer, phospholipids, and cyclodextrin.
[0195] In other embodiments, the drug-containing portion comprises a hydrophilic material, a pH-dependent material, or a hydrophobic material. The hydrophilic, pH-dependent, or hydrophobic material may be selected from one or more of the following pharmaceutical-grade polymers: copovidone (polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA), polyvinylpyrrolidone-polyvinyl acetate copolymer (PVP-VA) 60 / 40), cross-linked povidone, polyvinylpyrrolidone (PVP), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose or hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose phthalate (HPMCP), methylcellulose (MC), methacrylic acid copolymer, poly[butyl methacrylate, (2-dimethylaminoethyl) methyl methacrylate, methyl methacrylate] in a 1:2:1 ratio (e.g., EUDRAGIT® E 100, EUDRAGIT® E 12,5, EUDRAGIT® E PO), poly[ethyl acrylate, methyl methacrylate] in a 2:1 ratio (e.g., EUDRAGIT® NE 30 D, EUDRAGIT® NE 40 D, EUDRAGIT® NM 30). D) Poly[methacrylic acid, methyl methacrylate] in a 1:1 ratio (e.g., EUDRAGIT® L 100, EUDRAGIT® L 12,5, EUDRAGIT® L 12,5 P), poly[methacrylic acid, ethyl acrylate] in a 1:1 ratio (e.g., Acryl-EZE, Acryl-EZE 93A, Acryl-EZE MP, EUDRAGIT® L 30 D -55, EUDRAGIT® L 100-55, Eastacryl® 30 D, Kollicoat® MAE 30 DP, Kollicoat® MAE 100 P), and poly[methacrylic acid, methyl methacrylate] in a 1:2 ratio (e.g., EUDRAGIT® S 100, EUDRAGIT® S 12,5, EUDRAGIT® 12,5). Poly[methyl acrylate, methyl methacrylate, methacrylic acid] in a ratio of 7:3:1 (e.g., EUDRAGIT® FS 30 D), poly[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] in a ratio of 1:2:0.2 (e.g., EUDRAGIT® RL 100, EUDRAGIT® RL PO, EUDRAGIT® RL 30 D, EUDRAGIT® RL 12,5), and poly[[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] in a ratio of 1:2:0.2, and poly[ ...1. Poly[ethyl acrylate, methyl methacrylate, trimethylammonium chloride ethyl methacrylate] (e.g., EUDRAGIT® RS 100, EUDRAGIT® RS PO, EUDRAGIT® RS 30 D, EUDRAGIT® RS 12,5), polyethylene oxide (PEO), polyethylene glycol (PEG), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 57 / 30 / 13, polyethylene glycol-polyvinyl alcohol graft copolymer 25 / 75 (Kollicoat®) Ingredients include: IR), Kollicoat® IR-Polyvinyl Alcohol 60 / 40 (Kollicoat® Protect), Polyvinyl Alcohol (PVA), Hydroxypropyl Methylcellulose Succinate or Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS), Ethyl Cellulose (EC), Polyvinyl Acetate (PVAc) and Polyvinylpyrrolidone (PVP) 80 / 20, Polyvinyl Acetal Diethylamino Lactate (AEA), Carboxymethyl Ethyl Cellulose (CMCE), Carbomer, Phospholipids, Cyclodextrin.
[0196] In some embodiments, the material containing the drug layer may further include plasticizers and other additives. The plasticizer may be selected from any one or a combination of the following materials: triethyl citrate (TEC), vitamin E polyethylene glycol succinate (TPGS), acetic acid, acetylated triethyl citrate, tributyl citrate, o-acetylated tributyl citrate, polyhydroxy 15-hydroxystearate, polyoxyethylene-40 hydrogenated castor oil, polyoxyethylene ether (35) castor oil, dibutyl sebacate, diethyl phthalate, glycerin, methyl 4-hydroxybenzoate, castor oil, oleic acid, triacetic acid, and polyalkylene glycol. Other additives may be any one or a combination of the following materials: acacia, alginate, alginic acid, aluminum acetate, butylparaben, butylated hydroxytoluene, citric acid, calcium carbonate, candelilla wax, croscarmellose sodium carboxymethyl cellulose, confectionery, colloidal silica, cellulose, ordinary or anhydrous calcium phosphate, carnauba wax, corn starch, calcium carboxymethyl cellulose, calcium disodium EDTA, dicalcium hydrogen phosphate dehydrate, cetylpyridine, dicalcium hydrogen phosphate, tricalcium phosphate, dicalcium hydrogen phosphate, disodium hydrogen phosphate, dimethyl silicate, sodium erythritol, EDTA, gelatin, glyceryl oleate, iron oxide, ferric oxide Iron oxide yellow, iron oxide red, lactose (hydrated, anhydrous, monohydrate or spray-dried), microcrystalline cellulose, magnesium carbonate, magnesium oxide, methylparaben, polysorbate 80, propylparaben, potassium bicarbonate, potassium sorbate, potato starch, phosphoric acid, polyoxyethylene (40) stearate, sodium arc glycolate, pregelatinized starch, sodium crosslinked cellulose, sodium dodecyl sulfate, starch, silicon dioxide, sodium benzoate, sucrose, sorbic acid, sodium carbonate, sodium saccharin, sodium alginate, silicone, dehydrated sorbitol monooleate, sodium chloride, sodium metabisulfite, dehydrated sodium citrate, sodium starch, sodium carboxymethyl cellulose, succinic acid, sodium propionate, titanium dioxide, talc.
[0197] As shown in Figures 30 and 31, the drug dosage form 1500 is generally in the form of a disc. In some embodiments, the diameter of the disc structure does not exceed 22 mm and the thickness does not exceed 10 mm. In some embodiments, the unfolded dimension of the drug unit 1502 has a maximum length greater than 12 mm, preferably greater than 18 mm.
[0198] Figure 32 shows a top view of a drug dosage form 1600 according to an embodiment of the present invention. Figure 33 shows a perspective view of the drug dosage form 1600 shown in Figure 32 unfolded into a strip after the retaining member is removed. The housing portion 1621 and the retaining member portion of the drug dosage form 1600 are similar to those of the drug dosage form 1500, except that the housing portion 1621 of the drug unit 1602 defines two slots, in which drug-containing portions 1622 and 1623 are respectively embedded. In some embodiments, the drug-containing portions 1622 and 1623 contain different drugs. In other embodiments, the drugs in the drug-containing portions 1622 and 1623 are respectively mixed with materials with different dissolution rates, so that the desired drug release profile can be achieved by adjusting the ratio of drug-containing portions 1622 and 1623 on the drug unit. Although the drug-containing portions 1622 and 1623 shown are single-layer structures, they can also be constructed as multi-layer structures as shown above.
[0199] Drug Formulation III
[0200] The present invention also provides another pharmaceutical dosage form. This pharmaceutical dosage form includes a retaining member and a deploying member. The deploying member includes at least one elastic portion, configured to allow the deploying member to contract under a restraining force and return to its deployed shape when the restraining force is removed. In some embodiments, at least a portion of the elastic portion of the deploying member is curved or folded, for example, exhibiting a spring-like shape, a continuous S-shaped bend, a Z-shaped bend, or a figure-eight shape, thereby ensuring its elastic compression effect.
[0201] A retaining member is configured to surround the deploying member and apply a restraining force to the deploying member, thereby keeping the deploying member in a contracted shape. In some embodiments, the retaining member may be configured as a shell structure that completely covers the deploying member; in other embodiments, the retaining member may be a sleeve-like structure, a strip-like structure, etc., that surrounds only a portion of the deploying member. The retaining member contains a water-soluble material and is configured to remove the restraining force on the deploying member when the water-soluble material dissolves, thereby allowing the deploying member to be at least partially deployed.
[0202] Figures 34 and 35 illustrate an example of drug dosage form III. Specifically, Figure 34 shows a top view of drug dosage form 1700 according to an embodiment of the present invention. Figure 35 shows a top view of drug dosage form 1700 shown in Figure 34 unfolded after the retaining member is removed. As shown in Figures 34 and 35, the first portion 1701 and the second portion 1702 of the retaining member of drug dosage form 1700 together form a retaining member configured around and constraining the unfolding member 1703. The second portion 1702 of the retaining member comprises a water-soluble material or is composed entirely of a water-soluble material. In some embodiments, the aforementioned water-soluble material may include the list of water-soluble, fast-release thermoplastic materials used in the retaining member as described in the section on drug dosage form I of the present invention, which will not be repeated here. The first part 1701 of the retaining member is connected to the unfolding member 1703, as shown in Figure 35. Since the second part 1702 of the retaining member dissolves first, the first part 1701 of the retaining member unfolds together with the unfolding member 1703, and together with the unfolding member 1703, forms a structure that remains in the stomach or other parts of the upper digestive tract.
[0203] In some embodiments, the first portion 1701 of the retaining member may include a drug, for example, the retaining member 1701 may adopt the structure and materials of the "drug unit" described in drug dosage form I, thereby enabling the slow release of the drug in the stomach or other parts of the upper digestive tract. In other embodiments, the first portion 1701 of the retaining member may also include a portion of an enteric-coated drug or material, thereby enabling further drug release in the intestine when it subsequently enters the intestine. In some embodiments, the retaining member 1702 may also include a drug, such as a drug that needs to be released first in the stomach or upper digestive tract. Of course, the second portion 1702 of the retaining member may adopt a drug-loaded structure similar to the drug unit described in drug dosage form I, which will not be described further here. Although not shown, in some embodiments, the unfolding member 1703 may also include a drug, which will be detailed in the following embodiments.
[0204] Although the unfolding member 1703 shown in Figures 34 and 35 is an S-shaped continuous folding shape, in other embodiments, the unfolding member 1703 can be folded into any other shape that effectively reduces the extension length of the drug unit in a certain direction, such as a figure-eight or Z-shaped continuous folding shape, etc. In other embodiments, the unfolding member 1703 may also be strip-shaped when fully unfolded, or constructed into other elongated members of shapes that are easy to bend or fold, such as rope-shaped, rod-shaped, or cuboid-shaped. As shown in Figures 34 and 35, the unfolding member 1703 is constructed to extend generally along a plane. Compared to springs or other three-dimensional elastic structures, this construction is obviously more suitable for 3D printing and effectively improves the production efficiency of drugs.
[0205] Figure 36 shows schematic diagrams of three drug dosage forms similar to those shown in Figure 34. For simplicity, the structure corresponding to the second part 1702 of the holding member is not shown in the figure for any of the three drug dosage forms. As shown, although the unfolding members of the three drug dosage forms are all constructed as S-shaped continuous folds or bends similar to unfolding member 1703, the number of folds or bends differs. In other words, the folding spacing of each bend in the unfolding member of these three drug dosage forms is different. Specifically, as shown in the figure, the folding spacing of spring model 1 is 1.5 mm, the folding spacing of spring model 2 is 2 mm, and the folding spacing of spring model 3 is 3.5 mm. Table 1 shows the data of the original length, compressed length, and unfolded length after one hour in a gastric acid environment for the three drug dosage forms shown in Figure 36, while Figure 45 shows the size-time response curves corresponding to the three different drug dosage forms shown in Figure 36.
[0206] Table 1 Drug Dosage Form Length Original length / mm Compression length / mm Open 1h length / mm Model 1 (Spacing 1.5 mm) 21.53 13.01 22.20 Model 2 (Spacing 2 mm) 19.75 12.02 20.01 Model 3 (Spacing 3.5 mm) 23.09 13.00 21.18
[0207] As shown in Figure 36, the thickness of the unfolded component in all three models is 1 mm. As can be seen from Table 1 and Figure 45, when the ratio of the folding spacing of the unfolded component to the thickness of the unfolded component itself is less than 3:1, the drug dosage form can be administered in a smaller size and stably maintain the maximum unfolded size after unfolding without shrinking rapidly.
[0208] In some embodiments, the unfolding member of drug dosage form III also includes a first portion and a second portion. Figure 38 shows a top view of drug dosage form 1800 according to another embodiment of the present invention. Figure 39 shows a top view of drug dosage form 1800 shown in Figure 38 unfolded after a portion of the retaining member has been removed. As shown in Figures 38 and 39, drug dosage form 1800 includes a first portion 1801 and a second portion 1802 of the retaining member, which together constitute a retaining member surrounding the unfolding member and applying a binding force thereto. The construction and materials of the first portions 1801 and 1802 of the retaining members are generally similar to those described in the embodiment of Figure 34, and will not be repeated here.
[0209] Referring again to Figures 38 and 39, the unfolding component of the drug dosage form 1800 includes a first unfolding component 1803 and multiple second unfolding components 1804, 1805, 1806, and 1807 extending from the first unfolding component 1803. The second unfolding components 1804, 1805, 1806, and 1807 are respectively connected to the four first retaining components 1801. After the second retaining components 1802 dissolve and release the constraint on the unfolding component, under elastic action, the second unfolding components 1804, 1805, 1806, and 1807, which were previously in a bent state, extend outward and together with the four first retaining components 1801 form a structure with a certain unfolding size (e.g., greater than 16 mm), thereby achieving the previously mentioned gastric retention effect. It should be noted that, although the unfolding member shown in the figure includes four other parts of the unfolding member extending from the first part 1803 of the unfolding member and connected to the first part 1801 of the retaining member, in other embodiments, it may also be configured to have one, two, three, five, six or eight other parts of the unfolding member.
[0210] It should be noted that in some embodiments, the first part 1803 of the unfolding member may include a water-soluble material and is configured such that when the water-soluble material dissolves, the second to fifth parts of the unfolding member separate from each other, thereby effectively reducing the size of the overall drug dosage form and enabling it to be smoothly expelled from the stomach. Although not shown in the figure, in some embodiments, the connection points between the first part 1803 of the unfolding member and the unfolding member may also include water-soluble material, thereby achieving the disassembly effect of the overall structure as described above by dissolving the water-soluble material at these connection points. In some embodiments, the dissolution rate of the water-soluble material of the first part 1803 of the unfolding member or the water-soluble material at its connection points with other parts in the gastric juice is set to be less than the dissolution rate of the second part 1802 of the holding member, thereby enabling the drug dosage form to smoothly unfold into the structure shown in FIG39 that can achieve gastric retention, and after completing a certain period of gastric retention, it can be effectively decomposed and expelled from the stomach.
[0211] In some embodiments, the first portion 1801 of the retaining member, the second portion 1802 of the retaining member, or the first portion 1803 of the deploying member may include the "drug unit" structure and materials described in Drug Formulation I above to achieve drug loading and release. In other embodiments, the second to fifth portions extending from the first portion of the deploying member may also employ a similar drug loading result. In some embodiments, the second to fifth portions of the deploying member may include hydrophobic and enteric materials to achieve a gastric retention effect.
[0212] Figure 40 shows a top view of a pharmaceutical dosage form 1900 according to an embodiment of the present invention. Figure 41 shows a top view of the pharmaceutical dosage form 1900 shown in Figure 40 after the retaining member has been removed. As shown in Figures 40 and 41, the pharmaceutical dosage form 1900 includes a retaining member 1901, a first part 1902 of the unfolding member, and a second part 1903 of the unfolding member. The retaining member 1901 is a shell structure covering the first part 1902 and the second part 1903 of the unfolding member. Within the shell formed by the retaining member 1901, the first part 1902 and the second part 1903 of the unfolding member are cross-connected to each other, so that when the retaining member 1901 is at least partially dissolved and the constraint on the first part 1902 and the second part 1903 of the unfolding member is released, the cross-connection of the two can better achieve the gastric retention effect.
[0213] The first portion 1902 of the unfolding member may be configured as a drug-loaded structure and material including the "drug unit" described in drug dosage form I. For example, in some embodiments, each end of the first portion 1902 of the unfolding member includes at least one compartment, each compartment independently containing the same or different drugs. In some embodiments, the second portion 1903 of the unfolding member also includes drugs. In other embodiments, the retaining member 1901 also includes drugs that need to be released in the stomach in advance or rapidly, thereby achieving batch-by-batch, conditional release of the overall drug to achieve optimal therapeutic effect. In some embodiments, the connection points between the first portion 1902 and the second portion 1903 of the unfolding member include a water-soluble material, thereby achieving separation of the first portion 1902 and the second portion 1903 of the unfolding member after a certain period of time by dissolving the water-soluble material at these connection points, so as to facilitate its expulsion from the stomach.
[0214] Figure 42 shows a 3D simulation of the drug dosage form 1900 shown in Figure 40. Figure 43 shows the unconstrained unfolded component of the drug dosage form 1900 shown in Figure 40, the printed drug dosage form, and an actual picture of the unfolded drug dosage form.
[0215] It should be noted that the water-soluble materials mentioned in the various embodiments of drug dosage form III above may include the list of water-soluble fast-release thermoplastic materials used in the holding member as described in part of drug dosage form I of the present invention, which will not be repeated here. Furthermore, the material of the elastic portion used in the unfolding member can refer to the list of elastomeric materials defined in drug dosage form I. The materials included in the "drug unit" can be the specific materials and selections described in drug unit description in drug dosage form I, which will not be repeated here. In some embodiments, the drug dosage form may be formed by 3D printing. In some embodiments, at least a portion of the unfolding member or holding member of the above-mentioned drug dosage form further includes a swellable material, thereby enabling it to swell in gastric juice to cooperate with the unfolding of the unfolding member, achieving a better gastric retention effect and reducing the size of the product.
[0216] Method for 3D Printing Oral Drug Dosage Forms
[0217] This invention provides a method for preparing the pharmaceutical dosage form I of this invention using three-dimensional printing. In some embodiments, the method specifically includes: printing a pharmaceutical unit containing a drug; printing at least one unfolding member to connect the unfolding member to the pharmaceutical unit, and including at least one elastic portion configured to allow the unfolding member to take on a contracted shape close to the pharmaceutical unit under the action of a constraint force, and to return to an unfolded shape away from the pharmaceutical unit when the constraint force is removed; printing a holding member to connect the holding member to at least one unfolding member, and applying a constraint force to at least one unfolding member to allow the unfolding member to be in the contracted shape; wherein the holding member comprises a water-soluble material, and the holding member is configured to remove the constraint force on the unfolding member when the water-soluble material dissolves, thereby allowing at least one unfolding member to change from a contracted shape to an unfolded shape.
[0218] In some embodiments, the step of printing the holding member specifically includes: printing the holding member such that the holding member at least partially covers the drug unit and at least one unfolding member, thereby placing at least one unfolding member in a contracted shape. It should be noted that in some embodiments, the unfolding member of the printed drug dosage form may not include an elastic portion, and is configured to move from the contracted shape to the unfolded shape under the action of an external force. Specifically, in some embodiments, the unfolding member portion of the drug dosage form may include a thickness reduction portion with a thickness less than its adjacent portions. Because this thickness reduction portion is relatively more flexible, the unfolding member can still easily move from the contracted shape to the unfolded shape under the action of gastric juice or other substances. Drug dosage forms constructed with this thickness reduction portion can achieve a similar unfolding effect without the need for special elastic materials, thereby effectively reducing costs. Furthermore, since no elastic material is needed, when printing this drug dosage form using 3D printing technology, its unfolding member can be printed entirely using the same material, avoiding multiple switching of the print head. Simultaneously, the drug dosage form can be directly printed in a contracted shape, thereby effectively improving the production efficiency of the final product.
[0219] In some embodiments, the step of printing the holding member specifically includes: printing the holding member so that the holding member is disposed between and connected to the drug unit and the unfolding member, thereby placing the unfolding member in a contracted shape. In other embodiments, the drug dosage form to be printed includes multiple unfolding members, and the step of printing the holding member specifically includes: printing the holding member so that at least two unfolding members are connected by the holding member, thereby constraining the two unfolding members in a contracted state. In some embodiments, the drug unit of the drug dosage form includes a drug-containing portion and a drug-free portion, and the drug-containing portion is printed after the step of printing the holding member is completed.
[0220] The present invention also provides a method for preparing a pharmaceutical dosage form II using three-dimensional printing technology. The method includes: printing a pharmaceutical unit containing a drug, and making at least a portion of the pharmaceutical unit curved or folded; printing a holding member to connect the holding member to the pharmaceutical unit, and applying a restraining force to the pharmaceutical unit so that at least a portion of the pharmaceutical unit retains the curved or folded shape; wherein the holding member comprises a water-soluble material, and the holding member is configured to remove the restraining force on the pharmaceutical unit when the water-soluble material dissolves, thereby allowing at least a portion of the pharmaceutical unit to unfold from the curved or folded shape.
[0221] The present invention also provides a method for preparing pharmaceutical dosage form III using three-dimensional printing technology. The method includes: printing an unfolding member, the unfolding member including at least one elastic portion configured to allow the unfolding member to contract under a constraint force and to return to an unfolded shape when the constraint force is removed; applying a constraint force to the unfolding member to maintain the unfolding member in a contracted shape; printing a retaining member to retain the constraint force on the unfolding member, thereby maintaining the unfolding member in the contracted shape; wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the constraint force on the unfolding member when the water-soluble material dissolves, thereby allowing the unfolding member to at least partially unfold.
[0222] In some embodiments, the step of printing the holding member specifically includes: first printing the unfolding member; applying a constraint force to the printed unfolding member using a jig to make it shrink; while the unfolding member is in a shrinked state, first printing the first part of the holding member connected to the unfolding member, and then printing the second part of the holding member. In some embodiments, the step of printing the holding member specifically includes: first printing the holding member; printing the unfolding member, which is shrinking and under the constraint force of the holding member, within the area surrounded by the holding member, so that the unfolding member is connected to the holding member; the unfolding member includes at least one elastic portion, which is configured to at least partially unfold the unfolding member when the constraint force applied by the holding member is removed; and heat-treating the 3D-printed unfolding member to increase its elasticity. It should be noted that the terms "printing," "three-dimensional printing," "3D printing," "additive manufacturing," or their synonyms used in this invention refer to the technology of preparing three-dimensional objects (e.g., pharmaceutical dosage forms) by layering digital design. Basic techniques for 3D printing are described in U.S. patents US5204055, US5260009, US5340656, US5387380, US5503785, and US5633021. Other U.S. patents and patent applications related to 3D printing include: U.S. patents US5490962, US5518690, US5869170, US6530958, US6280771, US6514518, US6471992, and US8828411; and U.S. patent applications with publication numbers US2002 / 0015728, US2002 / 0106412, US2003 / 0143268, US2003 / 0198677, and US2004 / 0005360. The full text of the aforementioned U.S. patents and patent applications is incorporated herein by reference.
[0223] Several articles have also revealed 3D printing methods optimized for pharmaceutical dosage form manufacturing in terms of raw materials, equipment, and curing. Examples include adhesive deposition (see Gibson et al., Additive Manufacturing Technologies: 3D Printing, Rapid Prototyping and Direct Digital Manufacturing, 2nd Edition, Springer, New York, 2015; Katstra et al., 3D Printing for Oral Drug Dosage Forms, J Control Release, 66, 2000; Katstra et al., Manufacturing Complex Oral Drug Dosage Forms by 3D Printing, Materials Science and Engineering Dissertation, MIT, 2001; Lipson et al., Manufacturing: A New World of 3D Printing, John Wiley & Sons, Inc., 2013; Jonathan, Karim, 3D Drug Printing: A New Tool for Designing Custom Drug Delivery Systems, Int J Pharm, 499, 2016), and material jetting (see Jonathan, Karim, 3D Printing in the Pharmaceutical Field: A New Tool for Designing Custom Drug Delivery Systems, Int J Pharm, 499, 2016). Pharm, 499, 2016), extrusion (see Gibson et al., Additive Manufacturing Technologies: 3D Printing, Rapid Prototyping and Direct Digital Manufacturing, 2nd Edition, Springer, New York, 2015), and photopolymerization (see Melchels et al., Stereolithography and its Applications in Biomedical Engineering, Biomaterials, 31, 2010).
[0224] In some embodiments, the pharmaceutical dosage forms disclosed herein are 3D printed using extrusion. In some embodiments, the 3D printing method includes the use of a twin-screw extrusion method. During extrusion, material is extruded from a mechanically driven printing head through a printing nozzle. Unlike binder deposition, which requires a powder bed, extrusion can be used to print on any substrate. A variety of materials can be extruded for 3D printing, including the thermoplastics, pastes and colloidal suspensions, silicones, and other semi-solids disclosed herein. A common type of extrusion printing is fused deposition modeling, which uses solid polymer filaments for printing. In fused deposition modeling, a gear system drives the filament into a heated nozzle assembly for extrusion (see Gibson et al., Additive Manufacturing Technologies: 3D Printing, Rapid Prototyping, and Direct Digital Manufacturing, 2nd Edition, Springer, New York, 2015).
[0225] In some embodiments, the 3D printing method described herein includes a continuous feeding method.
[0226] In some embodiments, the 3D printing method described herein includes a batch feeding method.
[0227] In some embodiments, 3D printing is performed by fused deposition modeling (FDM). In some embodiments, 3D printing is performed by non-wire FDM. In some embodiments, 3D printing is performed by fused extrusion deposition (MED). In some embodiments, 3D printing is performed by inkjet printing. In some embodiments, 3D printing is performed by selective laser sintering (SLS). In some embodiments, 3D printing is performed by stereolithography (SLA or SL). In some embodiments, 3D printing is performed by PolyJet, Multi-Jet Printing System (MJP), Perfactory, Solid Object Ultraviolet-Laser Printer, Bioplotter, 3D Bioprinting, Rapid Freeze Prototyping, Benchtop System, Selective Deposition Lamination (SDL), Laminated Objet Manufacutring (LOM), Ultrasonic Consolidation, ColorJet Printing (CJP), EOSINT Systems, Laser Engineered Net Shaping (LENS) and Aerosol Jet System, Electron Beam Melting (EBM), Laser CUSING®, Selective Laser Melting (SLM), Phenix PXTM Series, Microsintering, Digital Part Materialization (DPM) or VX System execution.
[0228] In some embodiments, three-dimensional printing is performed by hot melt extrusion combined with 3D printing technology such as FDM. In some embodiments, the three-dimensional printing is performed by melt extrusion deposition (MED).
[0229] In some embodiments, methods for producing the oral drug dosage form described herein include 3D printing techniques, such as a combination of 3D printing and another method, for example, a combination of injection molding and 3D printing. In some embodiments, injection molding is used to form the shell, and 3D printing techniques are used to form one or more parts.
[0230] The method disclosed herein for 3D printing pharmaceutical dosage forms can generate instructions in various ways, including direct coding, export from solid CAD models, or through specific other means to the computer interface and application software of the 3D printer. These instructions may include information about the number and spatial location of droplets, as well as general 3D printing parameters, such as the droplet spacing for each linear dimension (X, Y, Z) and the liquid volume or mass of each droplet. For a given set of materials, these parameters can be adjusted to improve the quality of the created structure. The overall resolution of the resulting structure is a function of powder particle size, fluid droplet size, printing parameters, and material properties.
[0231] In some embodiments, the method includes creating a three-dimensional diagram of the oral drug dosage form based on predetermined parameters of the oral drug dosage form, wherein the three-dimensional diagram is created on a computer system. In some embodiments, the method includes converting (e.g., slicing) the three-dimensional diagram of the oral drug dosage form into three-dimensional printing code, such as G-code. In some embodiments, the method includes using a computer system to execute the three-dimensional printing code, thereby printing the oral drug dosage form described herein.
[0232] Example
[0233] The following will describe specific embodiments of printing drug dosage forms using the three-dimensional printing method, with reference to the diagrams in the instruction manual.
[0234] Example 1
[0235] The method of printing drug dosage form 400 using three-dimensional printing will be specifically explained in conjunction with Figures 7 and 8.
[0236] First, the drug unit 402 of the drug dosage form 400 shown in FIG. 7 and the unfolding member 401 in an unfolded shape are printed. Although the illustrated drug unit 402 is a cube, those skilled in the art will understand that the drug unit 402 can also be a cylindrical, capsule-shaped, or other oral drug form, having a shell portion and a drug-containing core. The shell has a "U"-shaped cross-section, and the drug core is loaded in a compartment formed by the shell. Furthermore, the shell portion is made of the same material as the unfolding member 401. The shell material of the drug unit 402 is composed of quaternary aminomethyl acrylate copolymer type B and ethyl cellulose; the drug-containing core is composed of a model drug and hydroxypropyl cellulose; and the material of the retaining member is polyvinylpyrrolidone Kollidon VA64. Specifically, the outer shell material (same as the unfolding component 401 material), the drug-containing core material, and the retaining component material of the drug unit 402 are respectively placed into a twin-screw extruder, and the extrusion temperature and screw speed of different functional blocks from the discharge port to the feed port heating end are respectively set. After mixing, melting, and extrusion, the materials are respectively conveyed to the printing head barrel of the drug 3D printer. The molten outer shell material (same as the unfolding component 401 material), the drug-containing core material, and the retaining component material enter the printing head 1, printing head 2, and printing head 3 respectively.
[0237] Set the barrel and nozzle temperatures of the 3D pharmaceutical printer to 50-80°C and 80-120°C respectively; set the printing pressure of the print head to 1-2 MPa; set the conveyor screw speed to 0.5-2 rpm. Open the D3 software, import the G-code set for the 3D slice of the pharmaceutical model, and begin printing the pharmaceutical units and the unfolding member 401 in the unfolded shape layer by layer as shown in Figure 7. Each layer is printed by switching between print head 1 and print head 2. The unfolding member 401 is connected to the bottom of the pharmaceutical unit 402, and the connection part is designed to be a thin connection based on the pharmaceutical model.
[0238] After printing the drug unit 402 and the unfolding member 401, a gripper, robotic arm, or other mechanical workpiece is used to fold the unfolding member 401 upwards to cover the drug dosage form 400 as shown in FIG. 8. Although the figure shows that 401 completely covers the upper surface of the drug unit 402, those skilled in the art will understand that by setting the length of the unfolding member 401, it is also possible to cover only the outer peripheral sidewalls of the drug unit 402, thus exposing the drug core on the upper surface of the drug unit 402.
[0239] Next, the print head 3, which is loaded with molten material for the retaining member, continues to print a seal on the upper part of the shrink-shaped drug dosage form 400 to print a coating on the retaining member, so that it wholly or partially covers the outer surface of the shrink-shaped drug dosage form 400. The retaining member of the drug dosage form 400 may also cover the intersection or close position of different unfolding members 401 after folding.
[0240] Example 2
[0241] The method of printing drug dosage form 700 using three-dimensional printing will be specifically described in conjunction with the structure of drug dosage form 700 shown in Figures 11 to 12.
[0242] First, the drug dosage form shown in FIG11 is printed, including a drug unit 702, an elastic portion 711, and an unfolding portion 701. The drug unit 702 includes a shell portion, a drug-containing core, and a plug, and the unfolding member 701 is made of the same material as the shell portion of the drug unit 702.
[0243] The drug unit is cylindrical with a U-shaped outer shell. The drug core is loaded in a compartment formed by the outer shell, and the compartment is sealed with a stopper. The outer shell material of the drug unit 702 is composed of quaternary aminomethyl methacrylate copolymer type B and ethyl cellulose; the drug-containing core is composed of model drug and hydroxypropyl cellulose; the stopper is composed of hydroxypropyl cellulose and triethyl citrate. The elastic part 711 is made of styrene block copolymer. The retaining member is made of polyvinylpyrrolidone Kollidon VA64. The outer shell material (same as the unfolding component material), drug-containing core material, plug material, elastic part material, and retaining component material of the drug unit are respectively fed into a twin-screw extruder. The extrusion temperature and screw speed of different functional blocks from the discharge port to the feed port heating end are set respectively. After mixing, melting, and extrusion, the materials are respectively conveyed to the printing head barrel of the drug 3D printing machine. The molten outer shell material (same as the unfolding component material), drug-containing core material, plug material, elastic part material, and retaining component material are respectively fed into printing head 1, printing head 2, printing head 3, printing head 4, and printing head 5.
[0244] Set the barrel and nozzle temperatures of the 3D pharmaceutical printer: barrel temperature 50-80℃, nozzle temperature 80-120℃; set the printing pressure of the print head to 1-2 MPa; set the conveyor screw speed to 0.5-2 rpm. Open the D3 software, import the G-code set for the 3D slice of the drug model, and begin printing the unfolded structure of the drug dosage form layer by layer, as shown in Figure 11. Each layer can be printed layer by layer by selecting print head 1, print head 2, print head 3, and print head 4.
[0245] After the unfolded structure is printed, use grippers, robotic arms or other mechanical workpieces to move the two unfolded components 701 to a contracted shape where the far ends are close to each other, as shown in Figure 12.
[0246] Subsequently, a retaining member 731 is printed between the distal ends of the two unfolding members 701 using a 3D printhead to connect their distal ends, and a retaining member 732 is printed between the drug unit 702 and the unfolding members 701. It should be noted that the retaining member 731 in Embodiment 3 can be connected by the unfolding members 701 by printing layer by layer in the vertical direction using a 3D printhead, or the retaining member 731 can be printed in the vertical direction using a five-axis 3D printhead.
[0247] Example 3
[0248] The method of printing drug dosage form 800 using three-dimensional printing will be specifically described in conjunction with Figures 13 to 16.
[0249] First, the drug unit 802 and the unfolding member 801 in the unfolded shape of the drug dosage form 800, as shown in Figures 13 and 14, are printed. The drug unit 802 has a shell portion and a drug-containing core, and its shell portion is made of the same material as the unfolding member 801. The shell material of the drug unit 802 is composed of quaternary amino methacrylate copolymer type B and ethyl cellulose; the drug-containing core is composed of model drug and hydroxypropyl cellulose; and the material of the retaining member 801 is polyvinylpyrrolidone Kollidon VA64. Specifically, the shell material (same as the unfolding member material), the drug-containing core material, and the retaining member material of the drug unit 802 are respectively placed into a twin-screw extruder, and the extrusion temperature and screw speed of different functional blocks from the discharge port to the feed port heating end are respectively set. After mixing, melting, and extrusion, the materials are respectively conveyed to the printing head barrel of the drug 3D printer. The molten shell material (same as the unfolding member material), the drug-containing core material, and the retaining member material enter the printing head 1, printing head 2, and printing head 3, respectively.
[0250] Set the barrel and nozzle temperatures of the 3D pharmaceutical printer to 50-80°C and 80-120°C respectively; set the printing pressure of the print head to 1-2 MPa; set the conveyor screw speed to 0.5-2 rpm. Open the D3 software, import the G-code set for the 3D slices of the pharmaceutical model, and begin printing the pharmaceutical units and the unfolded component 801 in the unfolded shape layer by layer as shown in Figure 13. Each layer is printed by switching between print head 1 and print head 2. The connection between the unfolded component 801 and the pharmaceutical unit 802 is designed to be a thinner connection based on the pharmaceutical model.
[0251] After the unfolding component 801 is printed, a gripper, robotic arm or other mechanical workpiece is used to fold the unfolding component 801 upward to cover the outer peripheral sidewall of the drug unit 802.
[0252] Next, the print head 3, which is loaded with molten material for holding member, continues to print on the upper part of drug unit 802 and unfolding member 801 to print the structure of holding member 803 as shown in FIG15 and 16, so that it covers the remaining part of the outer peripheral sidewall of drug unit 802, and covers unfolding member 803 in shrink shape and the upper surface of drug unit 802.
[0253] The drug dosage form 800 may also include an elastic portion that connects the unfolding member 801 and the drug unit 802. After the drug dosage form 800, constrained into a contracted shape, is administered to the human body, the elastic portion or elastic material allows the unfolding member of the drug dosage form to automatically return from a contracted shape to an unfolded shape as the retaining member 803 rapidly dissolves. For printing drug dosage forms with elastic portions, those skilled in the art will understand that by adding a print head 4 loaded with molten elastic material and switching between print heads 1, 2, and 4 to print layer by layer, the drug unit 802, the unfolding member 801, and the elastic portion connecting the two can be printed. Then, by using grippers, robotic arms, or other mechanical workpieces, the unfolding member 801 is folded upwards to cover the outer peripheral wall of the drug unit 902, and the elastic portion is in a deformed state. Finally, the print head 3, loaded with molten material for the retaining member, seals, covers, or adheres it to form a tablet of a size easily sized for oral administration by the patient.
[0254] Example 4
[0255] The method of printing drug dosage form 900 using three-dimensional printing will be specifically explained in conjunction with the structure of drug dosage form 900 shown in Figures 17 to 20.
[0256] First, the drug unit 902, the unfolding member 901, and the holding member 903, as shown in Figures 17 and 19, are printed. The drug unit 902 includes a shell portion and a drug-containing core, and the unfolding member 901 and the shell portion of the drug unit 902 are made of the same material. The shell material of the drug unit is composed of quaternary amino methacrylate copolymer type B and ethyl cellulose; the drug-containing core is composed of model drug and hydroxypropyl cellulose; and the material of the holding member is polyvinylpyrrolidone Kollidon VA64. The shell material (same as the unfolding member material), the drug-containing core material, and the holding member material of the drug unit are respectively fed into a twin-screw extruder. The extrusion temperature and screw speed of different functional blocks from the discharge port to the feed port heating end are set respectively. After mixing, melting, and extrusion, the materials are respectively conveyed to the printing head barrel of the drug 3D printer. The molten shell material (same as the unfolding member material), the drug-containing core material, and the holding member material are respectively fed into printing head 1, printing head 2, and printing head 3.
[0257] Set the barrel and nozzle temperatures of the 3D pharmaceutical printer to 50-80°C and 80-120°C respectively; set the printing pressure of the print head to 1-2 MPa; set the conveyor screw speed to 0.5-2 rpm. Open the D3 software, import the G-code set for the 3D slice of the drug model, and start printing the unfolded structure of the drug dosage form layer by layer, as shown in Figure 17. Each layer is printed layer by layer by switching between print head 1 and print head 2. The connection between the unfolding component 901 and the drug unit 902 is designed to be a thinner connection based on the drug model.
[0258] After the unfolded structure is printed, the unfolded component 901 is wound around the drug unit 902 into the contracted shape shown in FIG18 using grippers, robotic arms or other mechanical workpieces.
[0259] Next, the print head 3, which is loaded with molten material for holding member, continues to print on the upper part of drug unit 902 to print the structure of holding member 903 as shown in FIG19 and 20, so that it covers the upper half of the outer peripheral sidewall of drug unit 902 and the upper and outer peripheral side of unfolding member 903 in a contracted shape.
[0260] The drug dosage form may also include an elastic portion, which connects the unfolding member 901 and the drug unit 902. During printing, the elastic portion or elastic material causes the drug dosage form to roll or fold from an unfolded shape into a contracted shape. When administered to the human body, the elastic portion or elastic material causes the drug dosage form to return from a contracted shape to an unfolded shape. As will be understood by those skilled in the art, by adding a print head 4 loaded with molten elastic material and switching between print heads 1, 2, and 4 for layer-by-layer printing, the unfolded structure of the drug dosage form can be achieved. Then, by using grippers, robotic arms, or other mechanical workpieces, the elastic member and unfolding member 901 are deformed and rolled around the drug unit 902 into the contracted shape shown in Figure 18. Finally, the print head 3, which loads and holds the molten material of the holding member, seals, covers, or adheres it, producing a tablet of a size easily sized for oral administration by the patient.
[0261] The printing sequence in Embodiment 1 above can also be arbitrarily adapted. In addition, the unfolded member 901 in the shrinking shape can be printed directly in the mold without moving the unfolded member in the unfolding shape to the shrinking shape step.
[0262] Example 5
[0263] As described above, the unfolding member 901 may also recover from its contracted shape to its unfolded shape without relying on the elastic portion or elastic material. For example, the unfolding member 901 may include a relatively flexible, reduced-thickness portion, so that the unfolding member can still easily unfold from its contracted shape to its unfolded shape under the action of gastric juice or other substances.
[0264] For a drug dosage form constructed with unfolding members having a reduced thickness portion, it preferably includes multiple unfolding members, such as 3, 4, 5, or 6 unfolding members 101 as shown in FIG1. These unfolding members can pivot relative to their respective reduced thickness portions under the action of gastric juice or other substances. Since multiple unfolding members located at different positions on the outer peripheral wall of the drug unit rarely pivot to a contracted state simultaneously, the drug dosage form can still maintain a relatively unfolded shape in gastric juice to ensure a retention effect.
[0265] The structure of the drug unit and holding member is similar to that of Example 1. For drug dosage forms employing multiple unfolding members as shown in Figure 1, the overall printing method is the same as in Example 1. The difference lies in that the steps of printing the shell and unfolding members are adjusted to printing the shell and the unfolding member in a contracted shape, thus omitting the subsequent step of moving the unfolding member to the contracted shape. It should be emphasized here that printing the shell and the unfolding member in a contracted shape specifically includes printing the shell and the unfolding member, such that the unfolding member is close to the shell but maintains a certain gap to avoid adhesion between the two.
[0266] Example 6
[0267] The method of printing drug dosage form 1200 using three-dimensional printing will be specifically described in conjunction with Figures 22 to 26.
[0268] First, the drug dosage form shown in FIG26 is printed, including a drug unit 1204, a floating member 1207, a deploying member 1201, and a retaining member 1203. The drug unit 1204 includes a shell portion, a drug-containing core, and a plug 1205, the drug-containing core being loaded in a compartment 1206; and the deploying member 1201, the floating member 1207, and the shell portion of the drug unit 1204 are made of the same material.
[0269] The drug unit 1204 is enclosed by a shell forming multiple compartments. The drug core is loaded in the compartments 1206 formed by the shell and is not sealed with a stopper 1205. The shell material of the drug unit 1204 is composed of quaternary aminomethyl methacrylate copolymer type B and ethyl cellulose; the drug core is composed of a model drug and hydroxypropyl cellulose; the stopper is composed of hydroxypropyl cellulose and triethyl citrate. The material of the retaining member is polyvinylpyrrolidone Kollidon VA64. The outer shell material (same as the unfolding component material and the floating component material), the drug-containing core material, the plug material, and the retaining component material of the drug unit are respectively fed into a twin-screw extruder. The extrusion temperature and screw speed of different functional blocks from the discharge port to the feed port heating end are set respectively. After mixing, melting, and extrusion, the materials are respectively conveyed to the printing head barrel of the drug 3D printer. The molten outer shell material (same as the unfolding component material and the floating component material), the drug-containing core material, the plug material, and the retaining component material enter printing head 1, printing head 2, printing head 3, and printing head 4 respectively.
[0270] Set the barrel and nozzle temperatures of the 3D pharmaceutical printer: barrel temperature 50-80℃, nozzle temperature 80-120℃; set the printing pressure of the print head to 1-2 MPa; set the conveyor screw speed to 0.5-2 rpm. Open the D3 software, set the filling rate of the floating component to 10%; import the G-code set for the 3D slice of the drug model, and start printing the unfolded structure of the drug dosage form layer by layer. For each layer, the print head 1 can first print a floating component 1207 with a grid structure and an unfolding component 1201.
[0271] Subsequently, the unfolded member 1201 in the unfolded shape is moved to the contracted shape as shown in FIG26 using a gripper, robotic arm or other mechanical workpiece. Next, the holding member 1203 is printed using a print head 4 loaded with molten material of the holding member, so that the printed portion covers the outer peripheral wall of the floating member 1207 and the upper part of the unfolded member 1201.
[0272] After printing the floating component 1207, the unfolding component 1201 and the holding component 1203, the drug unit 1204 is then printed. Specifically, the outer shell, the drug-containing core loaded in the compartment 1206 and the stopper 1205 shown in FIG26 can be printed in layers alternately by printing head 1, printing head 2 and printing head 3.
[0273] It should be noted that, since the step of printing the drug-containing portion can be performed independently of other structures of the drug dosage form, the above printing method can employ any other design, method, and procedure for printing 3D drug dosage forms, thereby rapidly printing gastric retention dosage forms of the drug release structure. In some embodiments, the drug-containing portion may be printed first, followed by the printing of other portions of the drug dosage form.
[0274] Example 7
[0275] The method of printing drug dosage form 1500 using three-dimensional printing will be described in detail below with reference to Figures 30 and 31.
[0276] The drug unit 1502 includes a shell material 1521, a drug-containing layer 1522, and a retaining member 1503. The shell material is composed of one or more hydrophobic materials such as ethyl cellulose, polyethylene, beeswax, Eudragit RS, Eudragit RL; the drug-containing core contains the drug and is made of one or more of polyvinylpyrrolidone Kollidon VA64, Soluplus, polyethylene glycol (PEG200, PEG300, PEG400, PEG600, PEG1000, PEG1500), and polymethyl methacrylate (Eudragit E, L100, L100-55, S100); the retaining member is made of polyvinylpyrrolidone Kollidon VA64.
[0277] The outer shell material, drug-containing core material, and retaining component material of the drug unit are respectively fed into a twin-screw extruder. The extrusion temperature and screw speed of different functional blocks from the discharge port to the feed port heating end are respectively set. After mixing, melting, and extrusion, the materials are respectively conveyed to the printing head barrel of the drug 3D printer. The molten outer shell material (same as the unfolding component material), drug-containing core material, and retaining component material enter the printing head 1, printing head 2, and printing head 3 respectively.
[0278] Set the barrel and nozzle temperatures of the 3D pharmaceutical printer to 50-80°C and 80-120°C, respectively; set the printing pressure of the print head to 1-2 MPa; and set the conveyor screw speed to 0.5-2 rpm. Open the D3 software, import the G-code set for the 3D slice of the drug model, and begin printing the unfolded structure of the drug dosage form layer by layer, as shown in Figure 30. Each layer is printed layer by layer by switching between print head 1, print head 2, and print head 3. Specifically, the drug dosage form structure shown in Figure 30 is printed layer by layer using the above three 3D print heads in a spiral shape, with the drug units filling the gaps of the spiral shape.
[0279] Since the above method does not involve the step of mechanically moving the drug unit to bring it into a contracted shape, it can effectively improve product manufacturing efficiency and ensure the stability of the contracted shape configuration of the drug unit after printing. Furthermore, the above method allows designers to adjust the bending shape of the drug unit as needed, such as the S-shaped or Z-shaped folds described above, to adapt to different usage requirements. Of course, it is also possible to print different parts of the drug dosage form 1500 independently, for example, printing the drug unit 1502 in a spiral shape first, followed by printing the retaining member 1503 to fill the gaps between them.
[0280] The drug dosage form printed by the three-dimensional printing method described in Example 5 has a hydrophilic surface (containing the drug portion 1522) and a hydrophobic surface (shell portion 1521), so that after the holding member 1503 dissolves rapidly, it can unfold from a shape that is at least partially bent under the action of surface tension.
[0281] Example 8
[0282] The method of printing drug dosage form 1700 using three-dimensional printing will be specifically described in conjunction with the structure of drug dosage form 1700 shown in Figures 34 and 35.
[0283] First, the drug dosage form shown in FIG34 is printed, including a first part 1701 of retaining member, a second part 1702 of retaining member and an unfolding member 1703.
[0284] The material of the unfolding member 1703 is povidone Kollidon SR, and it has an S-shaped continuous folded shape. The first part 1701 of the retaining member is horseshoe-shaped and has internal compartments in which the drug is loaded. The material of the first part 1701 of the retaining member includes, but is not limited to, soluble materials as defined in drug dosage form I. The second part 1702 of the retaining member is connected to the first part 1701 of the retaining member, together forming an elliptical cylinder that surrounds the unfolding member 1703 in its contracted state. The second part 1702 of the retaining member includes, but is not limited to, water-soluble materials as defined in drug dosage form I. The unfolding component material, the first part of the retaining component material, and the second part of the retaining component material are respectively fed into a twin-screw extruder. The extrusion temperature and screw speed of different functional blocks from the discharge port to the feed port heating end are set respectively. After mixing, melting and extrusion, the materials are respectively conveyed to the printing head barrel of the pharmaceutical 3D printer. The molten unfolding component material, the first part of the retaining component material, and the second part of the retaining component material enter the printing head 1, printing head 2, and printing head 3 respectively.
[0285] Set the barrel and nozzle temperatures of the 3D pharmaceutical printer: barrel temperature 50 to 80°C, nozzle temperature 80 to 120°C; set the printing pressure of the print head to 1 to 2 MPa; set the conveyor screw speed to 0.5 to 2 rpm. Open the D3 software, import the G-code set for the 3D slice of the drug model, and begin printing the unfolded structure of the drug dosage form layer by layer, as shown in Figure 35.
[0286] After the unfolded component is printed, the first part of the retaining component is printed. The unfolded component and the first part of the retaining component are moved to a contracted shape with their far ends adjacent to each other using a gripper, robotic arm or other mechanical workpiece, as shown in Figure 34.
[0287] Subsequently, a second part 1702 of the retaining member is printed between the distal ends of the first part 1701 of the retaining member using a 3D printhead to connect the distal ends of the two.
[0288] The printing process of Example 8 can also be performed in the following order:
[0289] First, print the first part 1701 and the second part 1702 of the retaining member. Then, print the unfolding member 1703, which is under the constraint of the retaining member, within the area surrounded by the retaining member, so that the unfolding member 1703 is connected to the first part 1701 of the retaining member. After printing, heat-treat the unfolding member to increase the elasticity of the elastic part.
[0290] It should be noted that the second part 1702 of the retaining member in Embodiment 8 can be connected to the first part 1701 of the retaining member by printing layer by layer in the vertical direction using a 3D print head, or the second part 1702 of the retaining member can be printed in the vertical direction using a five-axis 3D print head.
[0291] Example 9
[0292] The method of printing drug dosage form 1800 using three-dimensional printing will be specifically described in conjunction with the structure of drug dosage form 1800 shown in Figures 38 to 39.
[0293] First, the drug dosage form shown in FIG38 is printed, including a first part 1801 of holding member, a second part 1802 of holding member, a first part 1803 of unfolding member, a second part 1804 of unfolding member and a third part 1805 of unfolding member.
[0294] The materials of the first part 1803 and the second part 1804 of the unfolding member include, but are not limited to, elastic materials as defined in drug dosage form I, and they are in an S-shaped continuous folded shape. The first part 1803 and the second part 1804 of the unfolding member are cross-connected to each other by the third part 1805 of the unfolding member. The material of the third part 1805 of the unfolding member includes, but is not limited to, soluble and corrosive materials as defined in drug dosage form I, and it has internal compartments in which the drug is loaded. The first part 1801 and the second part 1802 of the retaining member are arc-shaped and have internal compartments in which the drug is loaded. The material of the first part 1801 of the retaining member includes, but is not limited to, soluble and corrosive materials as defined in drug dosage form I. The material of the second part 1801 of the retaining member includes, but is not limited to, water-soluble materials as defined in drug dosage form I. The second part 1802 of the retaining member is connected to the first part 1801 of the retaining member, together forming a circle that surrounds the unfolding member in its contracted state. The materials of the first, second, and third parts of the unfolding component and the first and second parts of the holding component are respectively fed into a twin-screw extruder. The extrusion temperature and screw speed of the different functional blocks from the discharge port to the feed port heating end are set respectively. After mixing, melting, and extrusion, the materials are respectively conveyed to the printing head barrel of the pharmaceutical 3D printer. The molten materials of the first, second, and third parts of the unfolding component and the first and second parts of the holding component are respectively fed into printing head 1, printing head 2, printing head 3, printing head 4, and printing head 5.
[0295] Set the barrel and nozzle temperatures of the 3D pharmaceutical printer: barrel temperature 50-80℃, nozzle temperature 80-120℃; set the printing pressure of the print head to 1-2 MPa; set the conveyor screw speed to 0.5-2 rpm. Open the D3 software, import the G-code set for the 3D slice of the drug model, and begin printing the unfolded structure of the drug dosage form layer by layer, including the third, second, and first parts, as shown in Figure 39. Each layer can be printed layer by layer by switching between print head 1, print head 2, and print head 3.
[0296] After the unfolded component is printed, the first part of the retaining component is printed. The unfolded component and the first part of the retaining component are moved to a contracted shape with their far ends adjacent to each other using a gripper, robotic arm or other mechanical workpiece, as shown in Figure 38.
[0297] Subsequently, a second part 1802 of the retaining member is printed between the distal ends of the first part 1801 of the retaining member using a 3D printhead to connect the distal ends of the two.
[0298] The printing process of Example 9 can also be performed in the following order:
[0299] First, print the first part 1801 and the second part 1802 of the retaining member. Then, within the area surrounded by the retaining member, print the first part 1803, the second part 1804, and the third part 1805 of the unfolding member, which are under the constraint of the retaining member, so that the unfolding member is connected to the first part 1801 of the retaining member. After printing, heat-treat the unfolding member to increase the elasticity of the elastic part.
[0300] It should be noted that the second part 1802 of the retaining member in Embodiment 9 can be connected to the first part 1801 of the retaining member by printing layer by layer in the vertical direction using a 3D print head, or the second part 1802 of the retaining member can be printed in the vertical direction using a five-axis 3D print head.
[0301] Example 10
[0302] The method of printing drug dosage form 1900 using three-dimensional printing will be specifically explained in conjunction with the structure of drug dosage form 1900 shown in Figures 40 to 43.
[0303] First, the drug dosage form shown in Figure 34 is printed, including a holding member 1901, a first part of the unfolding member 1902, and a second part of the unfolding member 1903.
[0304] The material of the second part 1903 of the unfolding component is povidone Kollidon SR, and it has an S-shaped continuous folded shape. The first part 1902 of the unfolding component is dumbbell-shaped and has internal compartments in which the drug is loaded. The materials of the first part 1902 of the unfolding component include ethyl cellulose (EC), sorbitol (DBS), and titanium dioxide (TiO2). The retaining component 1901 covers the unfolding component in its contracted state. The materials of the retaining component 1901 include polyvinylpyrrolidone Kollidon VA64, hydroxypropyl cellulose (HPC), and triethyl citrate (TEC). The first part of the unfolding component material, the second part of the unfolding component material, and the holding component material are respectively fed into a twin-screw extruder. The extrusion temperature and screw speed of different functional blocks from the discharge port to the feed port heating end are set respectively. After mixing, melting and extrusion, the materials are respectively conveyed to the printing head barrel of the pharmaceutical 3D printer. The molten first part of the unfolding component material, the second part of the unfolding component material, and the holding component material enter the printing head 1, printing head 2, and printing head 3 respectively.
[0305] Set the barrel and nozzle temperatures of the 3D pharmaceutical printer: barrel temperature 50-80℃, nozzle temperature 80-120℃; set the printing pressure of the print head to 1-2 MPa; set the conveyor screw speed to 0.5-2 rpm. Open the D3 software, import the G-code set for the 3D slice of the drug model, and begin printing the second part 1903 and the first part 1902 of the unfolded structure of the drug dosage form layer by layer, as shown in Figure 41.
[0306] After the unfolded components are printed, the second part 1903 of the unfolded components is moved to a constricted shape with the far ends adjacent to each other using grippers, robotic arms or other mechanical workpieces, as shown in Figure 40.
[0307] Subsequently, a retaining member is directly printed on the unfolded member in the shrunken state using a 3D printhead to fill the gaps in the unfolded member and cover the unfolded member in the shrunken state.
[0308] The printing process of Example 10 can also be performed in the following order:
[0309] First, print the outer periphery of the retaining member 1901. Then, within the area surrounded by the outer periphery of the retaining member, print the first part 1902 and the second part 1903 of the unfolding member, which are under the constraint of the retaining member, so that the unfolding member is connected to the outer periphery of the retaining member. After the unfolding member is printed, print the retaining member directly on the unfolding member in the contracted state to fill the gaps in the unfolding member and cover the unfolding member in the contracted state.
[0310] Example 11
[0311] The retention effect of the drug formulation of Example 10 was verified under simulated human gastric acid conditions at 37°C in 900 mL of phosphate buffer solution with a pH of 1.0.
[0312] Table 2 Drug dosage form dimensions under simulated human gastric acid conditions Original length / mm Compression length / mm Open 1h length / mm 13.01 9.19 16.19
[0313] As shown in Figures 43-44 and Table 2, the drug formulation of Example 10 gradually unfolded in the phosphate buffer solution to reach a size greater than 16 mm and was able to maintain it for at least 10 hours, demonstrating a good gastric retention effect.
[0314] The pharmaceutical dosage forms disclosed in this invention can be printed on a commercial scale. For example, in some embodiments, the 3D printing method described in this disclosure can print approximately 10,000 to approximately 100,000 oral tablets per hour. In some embodiments, a commercial batch of oral pharmaceutical dosage forms has or substantially conforms to one or more predetermined dosage form characteristics described in this disclosure, including printing uniformity, accuracy of layer thickness, accuracy of layer surface area, accuracy of the mass fraction of active ingredient per layer, accuracy of the shape, size, and weight of the dosage form, accuracy of the active ingredient content, and accuracy of the active ingredient release profile. In some embodiments, at least about 80%, for example, at least about 85%, 90%, or 95% of a commercial batch of oral pharmaceutical dosage forms has or substantially conforms to one or more predetermined dosage form characteristics described in this disclosure, including printing uniformity, accuracy of layer thickness, accuracy of layer surface area, accuracy of the mass fraction of active ingredient per layer, accuracy of the shape, size, and weight of the dosage form, accuracy of the active ingredient content, and accuracy of the active ingredient release profile.
[0315] The drug dosage form disclosed in this invention directly prints the retaining member to constrain the drug dosage form structure in a contracted shape, avoiding the use of other loading containers such as capsules, reducing costs and improving production efficiency. In some embodiments, after the retaining member of the drug dosage form is printed, the outer shell of the drug dosage form is encapsulated by inkjet printing, making the outer surface smooth and aesthetically pleasing. Optionally, a logo, such as a company name or abbreviation, drug trade name, drug chemical name or abbreviation, specification, or a combination thereof, can also be printed on the outer surface of the drug dosage form by inkjet printing.
[0316] It should be noted that although different parts of the drug dosage form and sub-parts of these different parts have been mentioned in the detailed description above, this division is merely exemplary and not mandatory.
[0317] Although the principles of the invention have been described in conjunction with embodiments, it should be understood that these descriptions are for illustrative purposes only and are not intended to limit the scope of the invention. The content of this disclosure is for illustrative and explanatory purposes only and is not exhaustive or intended to limit the scope of the disclosure in any particular form. Many modifications and variations will be apparent to those skilled in the art. The selection of this disclosure is based on the aim of better explaining the principles and practical applications of the embodiments, thereby enabling those skilled in the art to understand various different embodiments and modifications made for specific applications. The scope of this disclosure is defined by the following claims or their equivalents. [Simplified Explanation of the Diagram]
[0053] The above and other features of the present invention will become more fully and clearly understood by means of the following description and the appended claims, in conjunction with the drawings. It is understood that these drawings depict only some embodiments of the present invention and should not be considered as limiting the scope of the present invention. The present invention will be explained more clearly and in more detail by means of the drawings.
[0054] FIG1 shows a perspective view of a drug dosage form 100 according to an embodiment of the present invention when its unfolding member 101 is in an unfolded shape.
[0055] Figure 2 shows a perspective view of the drug dosage form 100 shown in Figure 1 when its unfolding member 101 is in a contracted shape.
[0056] Figure 3 shows a perspective view of a drug dosage form 200 according to an embodiment of the present invention when its unfolding member 201 is not fully in a contracted shape;
[0057] Figure 4 shows a perspective view of the drug dosage form 200 shown in Figure 3 when its unfolding component 201 is in a contracted shape.
[0058] Figure 5 shows a perspective view of a drug dosage form 300 according to an embodiment of the present invention when its unfolding member 301 is in an unfolded shape;
[0059] Figure 6 shows a perspective view of the drug dosage form 300 shown in Figure 5 when its unfolding member 301 is in a contracted shape;
[0060] Figure 7 shows a perspective view of a drug dosage form 400 according to an embodiment of the present invention when its unfolding member 401 is in an unfolded shape;
[0061] Figure 8 shows a perspective view of the drug dosage form 400 shown in Figure 7 when its unfolding member 401 is in a contracted shape;
[0062] Figure 9 shows a top view of a drug dosage form 500 according to an embodiment of the present invention;
[0063] Figure 10 shows a top view of a pharmaceutical dosage form 600 according to another embodiment of the present invention;
[0064] Figure 11 shows a top view of a drug dosage form 700 according to an embodiment of the present invention, in which the unfolding member 701 is in an unfolded shape after the retaining member is removed;
[0065] Figure 12 shows a top view of the drug dosage form 700 shown in Figure 11;
[0066] Figure 13 shows a top view of a pharmaceutical dosage form 800 in an unfolded shape after the retaining member is removed, according to an embodiment of the present invention;
[0067] Figure 14 shows a front view of the drug dosage form 800 shown in Figure 13 in its unfolded shape after the retaining member is removed;
[0068] Figure 15 shows a front view of the drug dosage form 800 shown in Figure 13;
[0069] Figure 16 shows a cross-sectional top view of the drug dosage form 800 shown in Figure 13;
[0070] Figure 17 shows a perspective view of a pharmaceutical dosage form 900 in an unfolded shape after the retaining member is removed, according to an embodiment of the present invention;
[0071] Figure 18 shows a perspective view of the drug dosage form 900 shown in Figure 17 in a contracted shape after the retaining member is removed;
[0072] Figure 19 shows a perspective view of the drug dosage form 900 shown in Figure 17;
[0073] Figure 20 shows a frontal view of the cross-section of the drug dosage form 900 shown in Figure 17;
[0074] FIG21 is a cross-sectional front view of a drug dosage form 1000 according to an embodiment of the present invention;
[0075] Figure 22 shows a perspective view of a pharmaceutical dosage form 1100 in an unfolded shape after the retaining member is removed, according to an embodiment of the present invention;
[0076] Figure 23 shows a perspective view of the drug dosage form 1100 shown in Figure 22 in a contracted shape after the retaining member is removed;
[0077] Figure 24 shows a top view of the drug dosage form 1100 shown in Figure 22;
[0078] Figure 25 shows a cross-sectional front view of the drug dosage form 1100 shown in Figure 22;
[0079] Figure 26 shows a cross-sectional front view of a pharmaceutical dosage form 1200 according to an embodiment of the present invention;
[0080] Figure 27 shows a top view of a pharmaceutical dosage form 1300 according to an embodiment of the present invention;
[0081] Figure 28 shows a cross-sectional front view of the drug dosage form 1300 shown in Figure 27.
[0082] Figure 29 shows a cross-sectional front view of a pharmaceutical dosage form 1400 according to an embodiment of the present invention;
[0083] Figure 30 shows a top view of a pharmaceutical dosage form 1500 according to an embodiment of the present invention;
[0084] Figure 31 shows a perspective view of the drug dosage form 1500 shown in Figure 30 unfolded into a strip shape after the retaining member is removed;
[0085] Figure 32 shows a top view of a pharmaceutical dosage form 1600 according to an embodiment of the present invention;
[0086] Figure 33 shows a perspective view of the drug dosage form 1600 shown in Figure 32 unfolded into a strip shape after the retaining member is removed;
[0087] Figure 34 shows a top view of a drug dosage form 1700 according to an embodiment of the present invention;
[0088] Figure 35 shows a top view of the drug dosage form 1700 shown in Figure 34 with the unfolded component 1703 in the unfolded shape after the retaining component is removed;
[0089] Figure 36 shows a schematic diagram of three drug dosage form structures similar to those shown in Figure 34;
[0090] Figure 37 shows a picture of the drug dosage form 1700 shown in Figure 34 in its actual unfolded state;
[0091] Figure 38 shows a top view of a drug dosage form 1800 according to an embodiment of the present invention;
[0092] Figure 39 shows a top view of the pharmaceutical dosage form 1800 shown in Figure 38 when the unfolded component is in the unfolded shape after a part of the retaining component is removed;
[0093] Figure 40 shows a top view of a drug dosage form 1900 according to an embodiment of the present invention;
[0094] Figure 41 shows a top view of the drug dosage form 1900 shown in Figure 40 with the unfolding component in the unfolded shape after the retaining component is removed;
[0095] Figure 42 shows a 3D simulation of the drug dosage form 1900 shown in Figure 40;
[0096] Figure 43 shows an image of the unconstrained unfolding component of the drug dosage form 1900 shown in Figure 40, the drug dosage form (c), and the unfolded drug dosage form;
[0097] Figure 44 shows the size-time response curve corresponding to drug dosage form 1900 shown in Figure 40;
[0098] Figure 45 shows the size-time response curves corresponding to drug dosage forms with different elastic part structures as shown in Figure 36.
Claims
1. A dosage form of a gastric retention drug, comprising: A pharmaceutical unit, the pharmaceutical unit comprising a drug; At least one unfolding member is connected to the drug unit and is configured to have a contracted shape close to the drug unit and an unfolded shape away from the drug unit; The at least one unfolding member is connected to the at least one unfolding member and applies a constraint force to the at least one unfolding member to place the unfolding member in the contracted shape; wherein the holding member comprises a water-soluble material and is configured to remove the constraint force on the unfolding member when the water-soluble material dissolves, thereby allowing the at least one unfolding member to change from the contracted shape to an unfolded shape, wherein the unfolding member includes at least one elastic portion configured to allow the unfolding member to be in a contracted shape close to the drug unit under the constraint force and to return to an unfolded shape away from the drug unit when the constraint force is removed.
2. The gastric retention drug dosage form as claimed in claim 1, wherein the retaining member at least partially covers the drug unit and at least one unfolding member such that the at least one unfolding member is in a contracted shape; or wherein the retaining member is disposed between and connected to the drug unit such that the unfolding member is in a contracted shape; or wherein the gastric retention drug dosage form includes a plurality of unfolding members such that the retaining member connects at least two unfolding members such that the at least two unfolding members are in a contracted shape; or wherein the unfolding member has a reduced thickness portion at one end adjacent to the drug unit; or the unfolding member has a strip-like, petal-like, or rod-like shape; or wherein the gastric retention drug dosage form includes a plurality of unfolding members generally uniformly distributed along the periphery of the drug unit; or wherein the drug unit includes a hollow compartment; or the drug unit includes a shell and a drug-containing core, wherein the shell and the unfolding member contain the same body material.
3. The gastric retention drug formulation as claimed in claim 2, wherein the elastic portion is located at one end of the unfolding member adjacent to the drug unit.
4. A method for preparing a gastric retention drug dosage form using three-dimensional printing technology, the method comprising: The drug units and unfolding components are printed layer by layer so that the unfolding components are connected to the drug units; The unfolding member is constructed from an unfolded shape to a contracted shape close to the drug unit; a retaining member is directly printed to connect the retaining member to the at least one unfolding member, and the constraint force is applied to the at least one unfolding member to place the unfolding member in the contracted shape; wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the constraint force on the unfolding member when the water-soluble material dissolves, thereby allowing the at least one unfolding member to change from the contracted shape to the unfolded shape, wherein the at least one unfolding member is printed to include at least one elastic portion, the elastic portion being configured to allow the unfolding member to be in a contracted shape close to the drug unit under the constraint force, and to return to an unfolded shape away from the drug unit when the constraint force is removed.
5. The method of claim 4, wherein the print holding member comprises: Print the retaining member such that it at least partially covers or bonds the drug unit and at least one unfolding member, thereby placing the at least one unfolding member in a contracted shape; or print the retaining member such that it is positioned between and connected to the drug unit and the unfolding member, thereby placing the unfolding member in a contracted shape; or wherein the steps of printing at least one unfolding member and printing the retaining member are performed simultaneously or alternately by different printheads; or wherein the unfolding member is printed with a reduced thickness portion at one end adjacent to the drug unit. Alternatively, the printing of at least one unfolding member may include: printing at least one unfolding member in an unfolded shape; and moving the at least one unfolding member such that the unfolding member is in a contracted shape; or the drug unit may include a first portion containing a drug and a second portion not containing a drug, wherein the first portion containing a drug is printed after the step of printing the holding member is completed.
6. A dosage form of a gastric retention drug, comprising: An unfolding member, the unfolding member including at least one elastic portion, the elastic portion being configured to allow the unfolding member to contract under the action of a constraint force and to return to an unfolded shape when the constraint force is removed; And a retaining member disposed around the unfolding member and applying a restraining force to the unfolding member, thereby keeping the unfolding member in a contracted shape; wherein the retaining member comprises a water-soluble material and is configured to remove the restraining force on the unfolding member when the water-soluble material dissolves, thereby allowing the unfolding member to unfold at least partially.
7. A gastric retention drug formulation as claimed in claim 6, wherein the retaining member comprises a first portion and a second portion, the deploying member is connected to the first portion, and the second portion comprises a water-soluble material, and when the water-soluble material of the second portion dissolves, the retaining member removes the restraining force on the deploying member, thereby allowing the deploying member to at least partially deploy; or wherein when the deploying member is in the contracted configuration, the elastic portion of the deploying member is configured to extend substantially along a plane; or wherein when the water-soluble material of the retaining member dissolves at least partially, the length of the gastric retention drug formulation in at least one direction is greater than or equal to 16 mm; or wherein the deploying member is configured to fully deploy within at least 10 minutes after entering the gastric fluid.
8. The gastric retention drug formulation as claimed in claim 7, wherein the first portion comprises a first drug and the second portion comprises a second drug; or wherein the unfolding member comprises a first portion and a second portion, and the first portion of the unfolding member dissolves in gastric juice at a rate less than the second portion of the retaining member dissolves in gastric juice.
9. A gastric retention drug dosage form as claimed in claim 8, wherein the first portion includes at least one compartment in which the first drug is disposed; or wherein the first portion of the unfolding member includes the drug; or wherein the unfolding member further includes a third portion, wherein the first portion of the unfolding member is connected to the second portion of the unfolding member by means of the third portion of the unfolding member, and the connection between the first portion and the second portion of the unfolding member is broken when the third portion dissolves; or wherein the first portion of the unfolding member extends substantially along a first direction, and the second portion of the unfolding member extends substantially along a second direction, and the first portion and the second portion of the unfolding member are intersected and connected to each other.
10. The gastric retention drug formulation of claim 9, wherein the second and third portions of the deploying member comprise a hydrophobic material and an enteric material; or wherein the first portion of the deploying member comprises at least one internal compartment, and the internal compartment is disposed of a drug.
11. A method for preparing a gastric retention drug dosage form using three-dimensional printing technology, the method comprising: A printing unfolding member includes at least one elastic portion configured to allow the unfolding member to contract under a constraint force and return to an unfolded shape when the constraint force is removed; a constraint force is applied to the unfolding member to maintain it in the contracted shape; a printing retaining member is printed to retain the constraint force on the unfolding member, thereby maintaining the unfolding member in the contracted shape; wherein the retaining member comprises a water-soluble material and is configured to remove the constraint force on the unfolding member when the water-soluble material dissolves, thereby allowing the unfolding member to at least partially unfold.
12. The method of claim 11, wherein the retaining member comprises a first portion and a second portion, the method further comprising: After printing the unfolding component, the first portion of the retaining component is printed, such that the unfolding component is connected to the first portion of the retaining component; The first portion of the retaining member applies a constraint force to the unfolding member, thereby keeping the unfolding member in the contracted shape.
13. The method as described in claim 12, wherein the method further comprises: Print a second portion of the retaining member, wherein the second portion contains a water-soluble material, and when the water-soluble material in the second portion dissolves, the retaining member removes the restraining force on the unfolding member, thereby allowing the unfolding member to unfold at least partially.
14. A method for preparing a gastric retention drug dosage form using three-dimensional printing technology, wherein the method includes: Print holding components; An unfolding member, under the constraint of the retaining member, is printed within the area surrounded by the retaining member to connect the unfolding member to the retaining member. The unfolding member includes at least one elastic portion configured to at least partially unfold when the constraint applied by the retaining member is removed. The retaining member comprises a water-soluble material and is configured to remove the constraint on the unfolding member when the water-soluble material dissolves, thereby allowing the unfolding member to at least partially unfold.
Citation Information
Patent Citations
Expandable gastroretentive dosage form
CN106535878A
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
TW201834710A
Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
TW201834711A
Innovative methods of treatmenting tuberculosis
US20160074480A1
